

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Kantamneni, Shobha
Art Unit : 1617
Applicants : Kivlighn et al.
Serial No. : 09/892,505
Filed : June 28, 2001
For : Treatment For Cardiovascular Disease

DECLARATION OF GEORGE BAKRIS, M.D.

I, George Bakris M.D., hereby declare and say as follows:

THAT, I am Professor of Medicine and Director of the Hypertensive Diseases Center at the University of Chicago, Pritzker School of Medicine. I am a recognized world expert in the field of high blood pressure (see my curriculum vitae attached) and am also a member and coauthor of the Joint National Committee 7 on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure¹ which provides the primary guidelines for blood pressure management in the United States. I am well versed with the work of Dr Johnson as I have followed it from its beginnings in the mid to late 1990s and have also been moderator for many of the lectures he has given, including overseeing a debate on the role of uric acid that he had with members from the Framingham Heart Study group.

THAT, I am aware of the level of skill of one ordinarily skilled in the art of cardiovascular disease and kidney disease, and in particular, mechanisms of hypertension, d hereto; AND being thus duly qualified declare as follows:

1. Based on his experimental studies, Dr Johnson was the first to propose uric acid is a cause of hypertension². The novelty was the concept that uric acid caused hypertension, for the association had already been established. The longstanding belief, based on studies such as the Framingham Heart Study³, was that elevated uric acid in hypertension was a secondary phenomenon and not causative of hypertension. Moreover, the notion of prescribing medicines to lower uric acid for treating hypertension would have been considered, by experts in the field, as an improper and wasteful medical practice. As

such, we did not list uric acid as a risk factor for hypertension in the JNC7 report, nor was this done by any other major society.

2. I am aware that there were earlier studies in which it was reported that xanthine oxidase inhibitors could lower blood pressure in the spontaneously hypertensive rat (SHR)⁴. The authors of the SHR studies always thought that the xanthine oxidase inhibitors were functioning as antioxidants since they block xanthine oxidase-generated oxidants. In particular, never was efficacy linked with targeting uric acid levels to certain ranges. Moreover, the concept that these agents might be useful to treat hypertension was thwarted by the fact that these inhibitors did not lower BP in longterm studies in the SHR⁵⁻⁷. Incidentally, it should be noted that antioxidants have largely failed in the treatment of hypertension⁸. This does not mean that oxidants produced by xanthine oxidase may be important, for they could possibly play a role in hypertension. However, whether or not this occurs, the studies conducted in the SHR rat prior to 2001 did not provide a motivation to those skilled in the field to administer xanthine oxidase inhibitors to lower uric acid to a certain level as a means to lower hypertension. It bears repeating that controlling uric acid as a means to control hypertension was originally suggested by Dr. Richard Johnson.

3. I have read the editorial published in 1998 by Ward⁹ which is a mini-review of the theories concerning uric acid discussed in the literature at that time: some suggesting uric acid is a risk factor and some suggesting that uric acid is protective. The Ward paper does not assert either way whether uric acid is a risk factor or protective. The Ward paper clearly does not hypothesize nor suggest that uric acid plays a causative role in hypertension. It is important to understand that those skilled in the art of science and medicine are careful to not confuse something considered as a risk factor with something that is a causative factor. As an example, let's assume that a study finds that drinking alcohol is a risk factor associated with lung cancer. Those skilled in the art would not assume from this that drinking alcohol causes lung cancer (the medical community would undoubtedly interpret this study to mean that many people who drink also smoke). Likewise, when Ward or any similar paper in the literature prior to the Framingham Heart

Study discussed the possibility of uric acid as being a risk factor for hypertension, this was not interpreted to mean that uric acid caused hypertension. The only way to determine whether drinking alcohol causes lung cancer or to determine whether uric acid causes hypertension is to test the hypothesis by conducting a scientific study. The study conducted in the paper published by the Framingham Heart Study Group³ was directly tailored to examine the same theories regarding uric acid that were discussed by Ward. As alluded to above, the Framingham Heart Study Group emphatically concluded that uric acid does not have a causative role in cardiovascular disease. Furthermore, prior to Dr Johnson's work there was no proposed mechanism(s) by which uric acid might cause hypertension. Accordingly, the Ward paper itself did not provide a motivation in the art to control uric acid levels as a means to control hypertension.

4. The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information in belief are believed to be true; and further that these statements were made with the knowledge that willful false statements in the like so made are punishable by fine or imprisonment, or both, under §1001 of title 18 of the U.S.C. and that such willful false statements made jeopardize the validity of the application or of any patent issuing thereon.

Further declarant sayeth naught.



[name]

October 17, 2007

Date

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr., Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *Jama* 2003;289:2560-72.
2. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. *Hypertension* 2001;38:1101-6.
3. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. *Ann Intern Med* 1999;131:7-13.
4. Miyamoto Y, Akaike T, Yoshida M, Goto S, Horie H, Maeda H. Potentiation of nitric oxide-mediated vasorelaxation by xanthine oxidase inhibitors. *Proc Soc Exp Biol Med* 1996;211:366-73.
5. Laakso J, Mervaala E, Himberg JJ, Teravainen TL, Karppanen H, Vapaatalo H, Lapatto R. Increased kidney xanthine oxidoreductase activity in salt-induced experimental hypertension. *Hypertension* 1998;32:902-6.
6. Maenishi O, Ito H, Suzuki T. Acceleration of hypertensive cerebral injury by the inhibition of xanthine-xanthine oxidase system in stroke-prone spontaneously hypertensive rats. *Clin Exp Hypertens* 1997;19:461-77.
7. Trachtman H, Valderrama E, Futterweit S. Nephrotoxicity of allopurinol is enhanced in experimental hypertension. *Hypertension* 1991;17:194-202.
8. Ward NC, Croft KD. Hypertension and oxidative stress. *Clin Exp Pharmacol Physiol* 2006;33:872-6.
9. Ward HJ. Uric acid as an independent risk factor in the treatment of hypertension. *Lancet* 1998;352:670-1.

CURRICULUM VITAE

PERSONAL INFORMATION

NAME: George Louis Bakris, M.D., F.A.C.P., F.A.H.A., F.A.S.N

DATE OF BIRTH: June 15, 1952

BIRTHPLACE: Athens, Greece

CITIZENSHIP: U.S.A.

HOME ADDRESS: 1420 Wellington Terrace, Munster, IN 46321

BUSINESS ADDRESS: University of Chicago Pritzker School of Medicine,
Department of Medicine, Hypertensive Diseases Center, Section of
Endocrinology, Diabetes and Metabolism, 5841 S. Maryland
Ave., MC 1027, Room P-328A, Chicago, IL 60637

Administrative Asst.-Barbara-773.702.7936; FAX: 773.834.0486;

Direct Line-773.702.7930; email: gbakris@earthlink.net

MARITAL STATUS: Married, wife - Demetria

Two Children - Athena, 1986; Louis, 1991

EDUCATION

Undergraduate: Indiana University, Bloomington, IN

DEGREE: B.A., Biology and Psychology, 1974

Graduate: University of Chicago, Chicago, IL

DEGREE: M.A., Human Development, 1975

Thesis- Hypothalamic-Pituitary-Adrenal Axis & Norepinephrine

Metabolism in Depressive Illness; Advisor - John M. Davis, M.D.

Medical School: University Health Sciences/Chicago Medical School, No. Chicago,

DEGREE: M.D., Medicine, 1981

POSTGRADUATE CLINICAL AND RESEARCH TRAINING

Internship: *Internal Medicine*, 4/81-4/82

Mayo Graduate School of Medicine, Rochester, MN, Advisor - Randall Vollersten

Residency: *Internal Medicine*, 4/82-6/82

Mayo Graduate School of Medicine, Rochester, MN; Advisor - Randall Vollersten

Residency: *Psychiatry*, 7/82-6/83

Washington University School of Medicine, St. Louis, MO- Samuel Guze

Research Fellowship: Renal Physiology and Hypertension, 7/83-9/84

Mayo Graduate School of Medicine, Rochester, MN; Advisor - John C. Burnett, Jr.
Residency: *Internal Medicine*, 9/84-6/86
University of Illinois at Chicago; Advisor-Ruy Lorenzo
Fellowship: *Nephrology*, 7/86-6/88
University of Chicago Medical Center, Chicago, IL; Advisor - Adrian Katz
Fellowship: *Clinical Pharmacology*, 7/86-6/87
University of Chicago Medical Center, Chicago, IL; Advisor - Leon Goldberg,

PAST AND CURRENT ACADEMIC APPOINTMENTS

Current:

Professor of Medicine; Director, Hypertensive Diseases Center, Section of Endocrinology, Diabetes and Metabolism, University of Chicago Pritzker School of Medicine, 8/06-present

Past:

Professor (tenured), Departments of Preventive Medicine and Internal Medicine; Vice-Chairman, Department of Preventive Medicine; Director, Hypertension/Clinical Research Center -1/99-6/06
Director and Founder of Rush Hypertension Fellowship Program-6/93-6/06
Lecturer- Division of Nephrology, University of Illinois Medical Center 1/94-6/07
Associate Professor (tenured), Departments of Preventive Med and Internal Med 12/96-12/99
Assistant Professor, Departments of Preventive Med and Internal Med;4/93-12/96
Assistant Professor of Medicine and Pharmacology, Division of Nephrology & Director of Renal Fellowship Program University of Texas Health Science Center at San Antonio, 8/91 - 3/93
Staff Nephrologist and Director of Renal Research, Ochsner Clinic, New Orleans, LA- 8/88-7/91
Assistant Professor of Medicine, Section of Clinical Pharmacology, Tulane University School of Medicine, New Orleans, LA, 10/88 -7/91
Adjunct Assistant Professor of Physiology & Pharmacology, Tulane University School of Medicine, 10/88-7/91

BOARD CERTIFICATION:

Diplomate- National Board of Medical Examiners, 1982
Diplomate- American Board of Internal Medicine
Internal Medicine, September, 1986 (106504)
Diplomate- American Board of Internal Medicine
Nephrology, November, 1992 (106504)
Clinical Hypertension Specialist- Am. Society of Hypertension, 1999

LICENSURE:

Illinois	1986	Permanent	036-064409
Louisiana	1988	Permanent	07707 (Inactive)
Texas	1992	Permanent	J0912 (Inactive)

HONORS AND AWARDS:

Listed In America's Top Doctors-2006 &2007
Hellenic Medical Society of New York-Distinguished Physician Award, 2003
American Diabetes Association (Illinois Affiliate)-Father of the Year Award-2003
National Kidney Foundation of South Texas Award-For help organizing and making operational the San Antonio chapter, 1993
National Kidney Foundation National Award- Comprehensive Excellence in Medical Education, Boston, 1993
Chicago Medical School Scholastic Award 1981[This award is given to the student who had the highest grades on his/her clinical rotations].
Chicago Medical School, Dean's Award [This award is given to the top ten medical students of graduating class that have demonstrated outstanding scholastic achievement and best exemplify the ideals of the school.] 1981
Alpha Omega Alpha Medical Honor Society
Graduated in the upper 10% percent of medical class

PROFESSIONAL ORGANIZATIONS:

Fellow of:

American Society of Nephrology
American College of Clinical Pharmacology
The American College of Physicians
The American Heart Association (Council for the Study of High Blood Pressure
Council on the Kidney)

Member of

The American Society of Nephrology
The International Society of Nephrology
Central Society for Clinical Research
National Executive Boards
Board of Regents -American College of Clinical Pharmacology (1996-2005)
Hypertension Executive Council-National Kidney Foundation (1996-1999);(Chairman)-(1998-1999)
Member of National Kidney Foundation-President's Council (1999-present)
National High Blood Pressure Education Council (NHLBI-NIH)-JNC (2000-present)

EDITORIAL BOARDS:

Editor: Am. J of Nephrology (6/02-present)
Hypertension Section Editor: Up-To-Date - (7/06-present)

Associate Editor:

J Human Hypertension-(6/2007-present)
www.thekidney.org (Hypertension, Section Editor)-(6/2004-present)
Am. J Kidney Disease (1/02-6/04)
Translational Med. (7/01-present)

Kidney: Current Survey of World Lit. (10/93-1/2002)
J Clinical Pharmacology-Renal Section Editor (1/93-present)
Postgraduate Medicine - Nephrology Section Editor (1/92-present)

Member

Diabetes Care (2007-2009)
J of the Cardiometabolic Syndrome-(11/2005-present)
Advances in Chronic Kidney Disease (1/2003-present)
Am J Hypertension (11/99-2003)
Kidney International (7/99-1/02; 1/05-present)
Cardiovascular Drugs and Therapy (1/99-present)
J of Nephrology (1/97-present)
Hypertension (1/97-1/02; 1/03-present)
Hypertension, Dialysis & Clinical Nephrology (HDCN)-Internet J. (6/96-present)
Journal of Human Hypertension (12/94-present)
Journal of Diabetes and Its Complications (7/91-present)
Nephrology, Dialysis and Transplantation (1/02-present)

GUEST EDITOR: TOPICS

J Clinical Pharmacology-(Progression of Diabetic Renal Disease)- 4/95
J Human Hypertension – (The Lanai Symposium)-1/97
Coronary Artery Disease- (Renal Disease in the Elderly)-12/1997
Hypertension, Renal Section (Supplement to Annual HBPC Meeting)-1/1998
Mineral and Electrolyte Metabolism- (Renin Angiotensin System & Kidney In Diabetes)-January, 1999

ACADEMIC COMMITTEES (Past and Present)

Member, Research Advisory Committee, Ochsner Clinic (1/89-6/91)
Member, Medical Advisory Panel/Hypertension in Blacks - National Institutes of Health (NIDDK) [10/91-1/92]
Grant Reviewer-American Heart Association and National Kidney Foundation-National/Local (1991-present)
Chairman-Diabetic Nephropathy-Clinical, Program Committee, American Society of Nephrology Meeting- 1990,1992,1999
Co-Chairman- American Heart Assoc. Council on the Kidney-National Meeting. Preventing Progression of Diabetic Renal Disease- Dallas, TX, 1991
National Organizing Committee and Chairman of Symposium "Approaches to the Treatment of Diabetic Renal Disease", Am College of Clin Pharmacol (11/93)
Consultant-Cardio-Renal Advisory Board [FDA]-(1993-2002)
Member, Ad Hoc Review Committee for Program Projects-NHLBI [National Institutes of Health, 1992,1995,1997,1999, 2000
Clinical Research Center (GCRC) Review Committee, University of Texas Health Science Center, San Antonio (4/92-4/93)
Member-National High Blood Pressure Education Program Working Group on

Hypertension and Renal Disease - NIH (Heart, Lung and Blood Institute)1994
 Program Committee- AHA Blood Pressure Council (1996-1999)
 Writing Member, The Joint National Committee of the High Blood Pressure
 Education Program Working Group (JNC VI), NIH- 1997
 Chairman-Clinical Outcomes/Trials Program Committee, American Society of
 Nephrology Meeting- 1997
 Master's of Science in Clinical Research Program-(NIH K30) (Co-Principal
 Investigator) -Rush University Medical Center (1999-2005)
 Postgraduate Education Comm.-Am. Society of Nephrology (ASN)(2000-2006)
 Program Committee, Chairman- National Kidney Foundation-Annual Meeting (1998-2000)
 Executive Committee Member, The Joint National Committee of the High Blood
 Pressure Education Program Working Group (JNC 7), NIH (NHLBI)- 2002-2003
 NIH Clinical Trials Study Section-Ad hoc member (1999-2003)
 Rush University Continuing Medical Education Committee (2002-2006)
 American College of Clinical Pharmacology CME Committee (2000-present)

ADMINISTRATIVE POSITIONS IN NATIONAL ORGANIZATIONS (Past and Present)

USP Nephrology/Urology Expert Committee-Member-2007-present
 Chairman, Complications Committee-*American Diabetes Assoc.* (2004-2005 &06-07)
 Member/Vice-Chair, Institutional Review Board (IRB), *Rush University Medical
 Center-* (1998-2000)
 Member, Executive Research Council, *Am. Heart Assoc.*-IL Affiliate, 1995-1998
 Medical School Admissions Committee, *Rush Medical College* 1994-1997,
 Chairman, (1996-1997)
National Kidney Foundation, Illinois Affiliate Medical Advisory Board, Executive
 Committee, Chicago, 1995-present
 Member, Accreditation Committee, Louisiana State Continuing Medical
Education (CME) Board (12/89-7/91)
 Board of Directors, *National Kidney Foundation of Texas*(2/92-4/93)
 Member: Board of Regents- *Am. College of Clinical Pharmacology* (1997-2005)
 President, Hellenic Medical Society of Chicago, 1999-2000
 President, American College of Clinical Pharmacology, 2000-2002.
 Board of Directors, Member-International Soc. of Hypertension in Blacks (ISHIB)-2001-present

Listed in:

Top Physician's in America-2006, 2007
 Who's Who in the World-2002-present
 Who's Who (National Registry)-2002-present
 Who's Who in Medicine and Healthcare-2001-present
 Sterling's Who's Who in America-1999-present
 Scientific Committees of the American Heart Association-1991-present
 Who's Who In Diabetes (American Diabetes Association) -1999-present

RESEARCH ACTIVITIES

Current:

Relationships between changes in vascular compliance and blood pressure reduction with agents that inhibits inflammatory cytokines.

Clinical Trials that evaluate the effects of different antihypertensive therapy on kidney disease progression and cardiovascular outcomes

Previous:

Progression of diabetic renal disease: a) mechanisms of proteinuria (effects of drugs on glomerular permeability and changes in mesangium), b) development of clinical trials of renal disease progression and focus on lipid metabolism

Mechanisms of radio-contrast medium induced renal dysfunction.

Pharmacological effects of drugs on renal hemodynamics

Effects of vasoactive growth factors (ANG II, AVP, ET), insulin and glucose on the glomerular mesangial cell proliferation.

GRANT SUPPORT (current and previous)

National- G. Bakris-(Principal Investigator).

Admixture Mapping to Examine the Genetics of Hypertensive Kidney Disease in African-Americans- NIDDK (Co-Investigator)- submitted (2006)

AASK *Cohort Study* (African-American Study of Kidney Disease)- [UO1] (4/02-6/07)= \$1.5million

K30-Clinical Research Center Training Grant –Co-P.I. (7/99-7/05)-\$1 million

National Institutes of Health (NIDDK)-[U01 DK48643] (7/94-7/02)- *Progression* of Renal Disease in African Americans (AASK Trial)- \$3.2 million

National Institutes of Health (NHLBI)-[1P50HL55007-01] (2/96-1/01)- *Genetics*

of Hypertension in African-Americans-SCOR Grant-(Clinical Center) –Co-Investigator- PI Richard Lifton-Yale University- \$400,000

American Assoc. of Kidney Patients (12/88-12/89) - Effects of insulin and glucose on human mesangial cell mitogenesis and endothelin production-\$20,000.

Boehringer-Ingelheim- Research Fellowship in Clinical Pharmacology-1987-\$60,000

National Institutes of Aging (NIA)- Psychological and physiologic changes during the menopausal transition (Consultant)- (1995-1997)- \$7500- 3% effort

National Institutes of Health, NIDDK (1995-1997).Genetic Determinates of Nephropathy in NIDDM (Consultant) 10% effort-\$10,000/year-salary support.

National Institutes of Health, NIDDK [U01] (9/91-3/93) - Modification of Diet in Renal Disease (MDRD Trial) (co-investigator) - \$25,000/year, salary support

Local and Regional Grants - G. Bakris (Principal Investigator)

Alton Ochsner Medical Foundation Award (12/1/88-11/30/92) - The renal hemodynamic and cellular effects of calcium antagonists and converting enzyme inhibitors in diabetic dog - \$150,000.

American Heart Association, Louisiana Affiliate (7/90-6/91) - The effects of arginine vasopressin on mesangial cell growth and endothelin production in various glucose milieus -\$14,974.

American Diabetes Association, Louisiana Affiliate (7/89-6/90) - The effects of various hormones and glucose milieus on human mesangial cells growth - \$10,000.

Noel Foundation Research Award of the National Kidney Foundation of Illinois (1986-1987)-The role of oxygen free radical generation in radiocontrast medium-induced decreases in glomerular filtration rate - \$20,000

National Kidney Foundation of the Upper Midwest (7/1/84-6/30/85) – The contribution of oxygen free radicals in radiocontrast medium-induced renal hemodynamic changes - \$10,000

Investigator-Initiated Studies (Pharma. funding) -G. Bakris (Principal Investigator)

The protective effects of calcium antagonists on radiocontrast medium induced renal dysfunction - \$90,000.(1/87-1/88)

The renal effects of calcium antagonists and angiotensin converting enzyme inhibitors in the diabetic dog -\$60,000. (3/89-2/91)

A double blind placebo controlled multicenter trial evaluating the effects of misoprostol on renal hemodynamics following non-steroidal and anti-inflammatory drugs in diabetic man- \$130,000. (4/90-4/91)

The effects of combined therapeutic agents(calcium antagonists & ACE inhibitors) on renal preservation and proteinuria in diabetic subjects-\$149,000 (3/92-3/94)

The effects of different classes of calcium antagonists on glomerular permselectivity- \$300,000 (3/92-12/94)

The effects of similar classes of calcium antagonists on renal hemodynamics and albuminuria in type 2 diabetic patients –\$100,000 (5/92-4/93)

Double Blind Randomized Trial comparing the effects of different classes of calcium antagonist on changes in glomerular morphology in a remnant kidney model in the rat.-\$175,000 (1/95-6/97)-

Effects of combination therapy compared to either benazepril or amlodipine versus losartan on progression of glomerulosclerosis-\$109,000 (1997-1998)

The effects of valsartan on potassium homeostasis in patients with renal insufficiency-randomized, crossover, multicenter study -\$150,000 (8/97-8/99)

The effects of Lotrel on LDL cholesterol sub-fraction and glomerular permeability; a multicenter study -\$190,000 (9/97-9/99)-

The Effects of Nonionic versus Ionic Contrast Media on Renal Function: A double-blind trial, co-investigator- \$200,000 (6/89-6/91)

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial To Evaluate the Safety and Efficacy of Intravenous Auriculin Human Atrial Natriuretic Peptide in the Treatment of Acute Tubular Necrosis. (PI)- 60,000. (3/93-3/94)

INVEST Trial (International Verapamil SR-Trandolopril Study) Co-Investigator,

Regional Director. (7/97-2002)

The comparative effects of a COX2 inhibitor versus a COX1 inhibitor on renal function and blood pressure-120,000 (2000-2001)

The comparative effects of an ACE I or ARB on potassium homeostasis- Merck-140K (1999-2001)

The comparative effects of an ACE inhibitor, ARB or combination on proteinuria reduction when controlling for blood pressure reduction-King Pharma- 2003-2004 (\$135K)

Comparison of the long term effects of different beta blockers on components of the metabolic syndrome-The GEMINI Trial-Principal Investigator- 2003-2004 Glaxo Smith Kline-(150K)

Comparison of Different type of Combination Antihypertensive Therapy on Insulin Resistance and the Metabolic Syndrome-The STAR Trial-Principal Investigator-Abbott Labs –(2003-2005)-(100K)

Effects of PPAR gamma on inflammatory factors in metabolic syndrome-GSK (400K)-2007-2008)

NATIONAL/INTERNATIONAL CLINICAL TRIAL EXECUTIVE COMMITTEES:

VALUE
INVEST
ACCOMPLISH

DATA SAFETY MONITORING BOARDS-National Clinical Trials

CHICAGO trial-2003-2006

PERISCOPE-2003-2007

TAKEDA-Neuropathy Trial-Chair 2006-2007

TEACHING ACTIVITIES:

- ✦ Physical Diagnosis (basic and advanced)-Tulane University (8/89-6/91); University of Texas Health Science Center (8/91-3/93).
- ✦ Renal Pathophysiology lecture series (yearly) (8/91-3/93); University of Texas Health Science Center Nutrition lecture series (junior and senior medical students) (8/91-3/93); University of Texas Health Science Center at San Antonio
- ✦ Clinical Pharmacology Lecture Series (senior medical students/graduate students) (8/89-6/91)-Tulane University Medical School.
- ✦ Coordinator of the Renal Section - American College of Physicians -Update in 'Internal Medicine - (1992-1993)
- ✦ Coordinator of Renal Fellowship Training Program and Lecture Series- University of Texas Health Science Center at San Antonio (12/91-3/93)
- ✦ Coordinator of the Hypertension/Clinical Research Fellowship Training Program -Rush Presbyterian/St. Luke's Medical Center (4/93-present)
- ✦ Preventive Medicine/Hypertension Grand Rounds Director (1995-2002)
- ✦ Pathophysiology Lecture Series in Hypertension-Rush Medical College, Chicago(1/94-1/99)
- ✦ Annual Kidney Disease/Hypertension Lecture Series-Rush Graduate School of Nursing (1999-2006)
- ✦ Pathophysiology Lecture Series in Nephrology-University of Illinois Medical Center (1995-2000)
- ✦ Clinical Trials Course Director- for M. Sc. in Clinical Research Degree (K30)-Course Director-1999-2006)
- ✦ Harvard Nephrology Annual Board Review Update Course Lecturer (2000-2007)

POSTDOCTORAL FELLOWS SUPERVISED:

(* indicates academic appointments post fellowship)

1989-1991 Richard Slataper, MD*- *Oscher Clinic-Baton Rouge, LA*

1989-1990 Edward Sauter, MD*-*Assoc. Professor-MUSC*

1989-1991	Brian Demarie, MD-Practice
1990-1991	Vernon Valentino, MD-Practice
1990-1991	Bradley Barnhill, MD-Practice
1991-1993	Dan Riley, MD* Assoc Professor- U Texas Health Science Center-San Antonio
	Kevin Abbott, MD*-Professor & Director Clinical Nephrology-USHOES
1993-1994	David Hoelscher, MD-Practice
1994-1995	Amy Mangrum, MD*, Asst. Professor-UVA-Charolettesville
	Luke Kusmirek, MD*-Asst. Professor-U of Kentucky
1995-1996	Jung Yi, MD -Practice
1996-1997	Kostantinos Makrilakis, MD,PhD*-Assoc. Professor-U of Athens School of Medicine-GREECE
1997-1998	Imelda Villarosa, MD,-Practice
	Nauman Tarif, MD*-Assoc. Professor-Medical School PAKISTAN
1998-1999	Visclaw Drincic, MD-Geriatrics Practice
1999-2000	Unini Odama, MD-Endocrinology Practice
2000-2001	Munivar Izhar, MD*-Asst. Prof.-Rush Medical College
2001-2002	Jay Garg, MD*-Industry
2002-2003	Nicholas Kaperonis, MD-Asst. Professor (GREECE)
2002-2003	Renee Ellis, MD*-Nephrology Practice
2003-2004	David Chua, MD*-Instructor-UVA-Charolettesville
2004-2005	Ken Choi, MD-Practice
2005-2006	Nitin Khosla, MD-Postdoctoral Fellow-UCSD
2005-2006	Pantrelis Sarafidis, MD*-Postdoctoral Fellow (GREECE)
2006-2007	Atul Chugh, MD-
2007-2008	Irene Duka, MD

PUBLICATIONS - Original Papers

1. BAKRIS GL: Existential Psychology: A review. **J Instructional Psych.** 1977; 4: 13-20.
2. BAKRIS GL, Vernasco K, Verongas D:The consistency model of personality: An overview. **J Instructional Psych** 1980;7:71-76.
3. BAKRIS GL, Smith DW, Tiwari S: Dermatologic manifestations of lithium: A review **International J. of Psychiatry in Medicine** 1981;10:327-331.
4. BAKRIS GL, Taylor MA, Mulopulos GP, Wawczak S: Lithium prophylaxis and the kidney. **J. of Affective Disorders** 1981;3:37-42.
5. Tiwari S, BAKRIS GL: Psychogenic vertigo:A review. **Postgraduate Med.** 1981; 70:69-77
6. BAKRIS GL, Mulopulos GP, Tiwari S, Franklin C: Orphenadrine citrate: An alternative for muscle contraction headaches. **Illinois Med J** 1982;161:106-108.
7. BAKRIS GL: Clonidine for opiate withdrawal in the chronic pain patient. **Postgraduate Medicine** 1982; 71:240-241.
8. BAKRIS GL, Cross PD, Hammarsten J: The use of clonidine for management of opiate abstinence in a chronic pain patient. **Mayo Clinic Proc** 1982;57:657-660

9. Petrucci B, BAKRIS GL, Miller T, Korpi E, Linnoila M: A liquid chromatographic assay for 5-hydroxy-tryptophan, serotonin and 5-hydroxyindoleacetic acid in human body fluids. **Acta Pharmacol et Toxicol** 1982;51:421-427.
10. BAKRIS GL, Mulopulos GP, Horchik R, Ezdinli EZ, Ro J, Yoon B: Pulmonary scar carcinoma: A clinic-pathologic analysis. **Cancer** 1983;52:493-497.
11. BAKRIS GL, Cross PD, Hammarsten J: Disopyramide associated liver dysfunction. **Mayo Clinic Proceedings** 1983;58:265-267.
12. BAKRIS GL, Zorumski CF: Chronic Pain: A pharmacologic review and behavior modification approach. **Postgraduate Medicine** 1983;73:119-128.
13. Zorumski CF, BAKRIS GL: Lithium associated choreoathetosis: A case report and literature review. **Am J Psychiatry** 1983;140:1621-1622.
14. BAKRIS GL, Burnett JC, Jr.: A role for calcium in radiocontrast-induced alterations in renal hemodynamics. **Kidney International** 1985;27:465-468.
15. BAKRIS GL, Wilson DM, Burnett JC, Jr The renal forearm and hormonal responses to standing in the presence and absence of propranolol. **Circulation** 1986;74: 1061-1065.
16. Arend L, BAKRIS GL, Burnett JC, Jr., Megerian C, Spielman WS: A role for intra-renal adenosine in the renal hemodynamic response to contrast medium. **J. Lab. Clin. Med.** 1987;110:406-411.
17. BAKRIS GL, Weber R, Nelson K, Elliott W, Kaplan E, Murphy MB: Comparison of the effects of dopamine and fenoldopam, a selective dopamine-1 agonist, on parathyroid hormone release in man. **Mineral and Electrolyte Metabolism** 1988; 14(6):343-346.
18. BAKRIS GL: The effects of oral ingestion of a nitroglycerin transdermal patch. **JAMA** 1988; 260:1243-1244.
19. BAKRIS GL, Kern S: The clinical spectrum of nonsteroidal anti-inflammatory drug-induced renal dysfunction: A review. **Am. Family Physician** 1989; 40(4):199-204.
20. BAKRIS GL, Frohlich ED: Early identification of target organ damage in man with essential hypertension. **Practical Cardiology** 1989;15(5):60-76.
21. BAKRIS GL, Frohlich ED: The evolution of antihypertensive therapy: four decades of experience. **J. Am. Coll. Cardiol.** 1989;14(7):1595-1608
22. BAKRIS GL, Jones J, Lass N, Gaber O, Burnett JC, Jr.: Radiocontrast medium-induced declines in renal functions: A role for oxygen free radicals. **Am. J. Physiol** 1990;258 (Renal Fluid Electrolyte):F115-F120.
23. BAKRIS GL, Gaber DA, Jones JD: Oxygen free radical involvement in urinary Tamm- Horsfall protein excretion after intrarenal injection of contrast medium. **Radiology** 1990;175:57-60.
24. Sauter E, BAKRIS GL: The effects of enalapril on urinary protein excretion in patients with idiopathic membranous nephropathy. **J. Clin Pharmacol** 1990; 30:155-158.
25. BAKRIS GL: The comparative effects of diltiazem and lisinopril on urinary protein excretion in diabetic patients. **Ann Intern Med** 1990;112(9):707-708.
26. Porile JL, BAKRIS GL, Garella S: Acute interstitial nephritis with glomerulopathy due to nonsteroidal anti-inflammatory agents: A review of its clinical spectrum and effects of steroid therapy. **J. Clinical Pharmacology** 1990;30:468-475.
27. BAKRIS GL, Sauter ER, Hussey J, Fischer J, Gaber AO, Winsett R: Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. **N Engl. J. Med.** 1990;323:86-90.

28. BAKRIS GL and Frohlich ED: Calcium antagonists: new indications. **Curr. Opinion in Cardiol.**1990;5(5):630-634.
29. Demarie B, BAKRIS GL: Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. **Annals of Internal Med.** 1990; 113(12):987-988.
30. Karp S, BAKRIS GL, Rubenstein D, Hou S: Tobramycin induced exfoliative dermatitis in a peritoneal dialysis patient. A case report and literature review. **Cutis** 1991;18:167-168.
31. BAKRIS GL, Fairbanks RF, Traish A, with technical assistance by Akerstrom V, and Kern S: Arginine vasopressin stimulates human mesangial cell production of endothelin. **J. Clin Investigation**, 1991;87:1158-1164
32. Valentino V, Wilson M, Weart W, and BAKRIS GL: Effects of calcium antagonists and angiotensin converting enzyme inhibitors on diabetic nephropathy: **Arch Intern Med.** 1991;151:2367-2374.
33. BAKRIS GL and Gavras H: Hypertension in the Elderly: An editorial review. **Geriatric Nephrol and Urology**, 1991;1:121-127.
34. BAKRIS GL. Renal effects of calcium antagonists in diabetes mellitus: An overview of studies in animal models and in humans. **Am. J. Hypertens** 1991;4(Suppl II):487S-493S.
35. BAKRIS GL. The effects of calcium antagonists on renal hemodynamics, urinary protein excretion and glomerular morphology in diabetic states. **J. Am. Soc. Nephrology** 1991; 2 (Suppl 1):S21-S29.
36. Valentino V and BAKRIS GL: Clinical management of isolated systolic hypertension. **Practical Cardiology** 1991;17(6):26-30.
37. Weir MR and BAKRIS GL: Risk for renal injury in diabetic hypertensive patients. **Postgraduate Med.** 1992;91(3):77-95
38. BAKRIS GL, Barnhill BW, Sadler R: Treatment of arterial hypertension in diabetic man: Importance of therapeutic selection. **Kidney International**, 1992;41(4): 912-919.
39. Slataper R and BAKRIS GL: Clinical management of hypertension in patients with diabetic nephropathy. **Drug Therapy** 1992;22:35-46.
40. BAKRIS GL: The antiproteinuric effect of antihypertensive agents in diabetic nephropathy. **Arch. Intern. Med.** (letter)1992;152:2137-2139.
41. Cook J, Chen Li, BAKRIS GL, Bhandaru S, Re RN: The use of antisense oligonucleotides to establish autocrine angiotensin growth effects in human neuroblastoma and mesangial cells. **Antisense Res and Develop.** 1992;2:199-210
42. BAKRIS GL: Hypertension in diabetic patients: An overview of interventional studies to preserve renal function. **Am J Hypertens** 1993;6(4):140S-147S
43. Abbott K, BAKRIS GL: Renal effects of antihypertensive medications: An overview. **J Clinical Pharmacol** 1993;33(5):392-399
44. Weir M, BAKRIS GL: Albuminuria in hypertensive diabetics: Is it an important variable in treatment? Proceedings of a symposium. Minneapolis: **Postgraduate Med** 1993;92:23-30
45. Slataper R, Vicknair N, Sadler R, and BAKRIS GL: Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. **Arch. Intern Med** 1993;153:973-980
46. BAKRIS, G. Diabetic Nephropathy: what the clinician needs to know to preserve kidney function. **Postgraduate Med.**1993;93(5):89-100
47. Committee on the Biology of Kidney Disease and Hypertension in Blacks. Clinical research subcommittee recommendations. **Am J Kidney Dis** 1993;21 (Suppl.1): 85-87.

48. Brown S, Walton C, Crawford P, and BAKRIS GL. Comparative renal hemodynamic effects of an ACE inhibitor or calcium antagonist on progression of diabetic nephropathy in the dog. **Kidney International** 1993;43:1210-1218.
49. BAKRIS GL. Angiotensin converting enzyme inhibitors and progression of diabetic nephropathy. **Ann Intern Med.** 1993;118(8): 643-644.
50. BAKRIS GL and Re RN with technical assistance of Srinivas Bhandaru: Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. **Am. J. Physiol.** 1993;264 (Renal and Electrolyte Physiol. 33):F937-F942.
51. BAKRIS, GL and Stein JH: Diabetic Nephropathy. **Disease-a-Month** 1993;39(8): 573-612
52. BAKRIS, GL and Talbert R. A simplified method for determining drug dosage in patients with renal insufficiency. **Postgraduate Med.** 1993;94(12):153-164.
53. BAKRIS, GL. Effects of ACE inhibitors on renal and overall mortality. **Ann Intern Med** 1993;119(8):860-861
54. BAKRIS GL and Mazzaferri EL: Severe Hypertension in a Young Patient. **Hospital Practice** 1993; 28:57-64
55. Abbott, K , Sanders L and BAKRIS, GL : Microalbuminuria in Type II diabetic patients: implications for prognosis and therapy. **Arch. Intern Med.**1994; 154: 146-153
56. Slataper R, Vicknair N, Sadler R, BAKRIS GL. ACE inhibition normalizes renal size and microalbuminuria in normotensive insulin dependent diabetic patients. **J Diabetes Complications.**1994;8:2-6.
57. Hoelscher D and BAKRIS GL: Slowing progression of diabetic nephropathy with appropriate antihypertensive therapy **J Cardiovasc Pharmacol** 1994; 23(Suppl.1): S34-S38.
58. BAKRIS GL. Blood pressure control and progression of diabetic nephropathy: Are all drugs created equal? **Kidney: A Current Survey of World Literature.** 1994;3:61-62.
59. Klahr S, Levey AS, Beck GJ, et. al. for the Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. **N Engl J Med** 1994; 330: 877-884.
60. Riley DJ, Weir M, BAKRIS GL: Renal adaptation to the failing heart: Understanding the cascade of responses. **Postgraduate Med.** 1994;95:141-150
61. Riley DJ, Weir M, BAKRIS GL:Renal adaptation to the failing heart: Avoiding a therapeutic misadventure **Postgraduate Med.** 1994; 95:153-156.
62. BAKRIS GL. Diabetic Renal Disease: An overview of concepts and intervention. **Focus & Opinion: Internal Medicine** 1994;1 (2): 7-11.
63. Gaber L, Walton C, Brown S, BAKRIS, GL: Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. **Kidney Int.**1994;46:161-169
64. BAKRIS, GL, Bhandaru S, Akerstrom V and Re RN. ACE inhibitor mediated attenuation of mesangial cell growth: A role for endothelin. **Am J Hypertens.** 1994;7(7):583-590
65. Kilaru P and BAKRIS GL. Microalbuminuria and progressive renal disease. **J Human Hypertens** 1994;8:809-817
66. Rudnick MR, Goldfarb S, Ludbrook PA, et.al., for the Iohexol Cooperative Study Group. Nephrotoxicity of Ionic and Nonionic Contrast Media in 1196 Patients: A Randomized Trial. **Kidney International**, 1995; 47:254-261
67. Hoelscher D, Weir MR, BAKRIS GL. Hypertension in diabetic patients: An update of interventional studies to preserve renal function. **J Clin Pharmacol** 1995;35:73-80.

68. BAKRIS GL, Starke U, Heifets M, Polack D, Smith M, Leurgans S. Renal effects of oral prostaglandin supplementation following ibuprofen in diabetic subjects: A double blind, placebo controlled multicenter trial. **J Am Soc Nephrol.**1995; 5(9): 1684-1688
69. BAKRIS GL. Pathogenesis of hypertension in diabetes **Diabetes Rev** 1995;3(3): 460-476.
70. Lash JP and BAKRIS GL. Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. **Nephrol. Dialysis and Transpl.** 1995;10(Suppl.9):56-62
71. BAKRIS GL and Williams B. ACE inhibitors and calcium antagonists alone or combined: Is there a difference on progression of diabetic renal disease. **J Hypertension** 1995;13(suppl 2):S95-S101
72. Kilaru PK and BAKRIS GL. ACE Inhibition or calcium channel blockade: Renal implications of combination therapy versus a single agent. **J Cardiovasc. Pharmacol**, 1996;28:S34-44
73. Abbott K, Smith AC, BAKRIS GL. Effects of dihydropyridine calcium antagonists on albuminuria in diabetic subjects. **J. Clin Pharmacol.** 1996;36:274-279.
74. BAKRIS GL, Smith AC. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. **Annals of Int Med** 1996;125(3):201-203
75. BAKRIS GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy: Results of a six year study. **Kidney International**, 1996;50:1641-1650.
76. Kuzmirek SL and Bakris GL. The kidneys in cardiovascular disease: victim or culprit? (invited editorial) **Br J of Cardiology** 1996;3:145-147.
77. Bakris GL. Microalbuminuria: Prognostic Implications. **Curr Opin in Nephrol and Hypertens** 1996;5(3): 219-223.
78. National High Blood Pressure Education Program Working Group. 1995 Update of the working group reports on chronic renal failure and renovascular hypertension. **Arch Intern Med.** 1996; 156:1938-1947
79. Epstein M and BAKRIS GL. Newer approaches to antihypertensive therapy: use of fixed dose combination therapy **Arch Intern Med** 1996; 156:1969-1978
80. BAKRIS GL, Weir, MR, Sowers JR. Therapeutic challenges in the obese, diabetic patient with hypertension. **Am J Med.** 1996;101:335-46S.
81. BAKRIS GL and Weir MR. Salt intake and reductions in arterial pressure and proteinuria: Is there a direct link? **Am J Hypertens.** 1996;9:200S-206S
82. BAKRIS GL. Is the level of blood pressure reduction important for preservation of renal function? (editorial) **Nephrol Dial Transpl** 1996;11(12): 2383-2384.
83. Cziraky MJ, Mehra IV, Wilson MD, BAKRIS GL. Current Issues in treating the hypertensive patient with diabetes: focus on diabetic nephropathy. **Ann of Pharmacotherapy** 1996;30: 791-801.
84. BAKRIS GL and Shaikh, M Calcium channel blockers and progression of renal disease: clinical studies put into perspective. **J. Nephrology** 1996;9(6):263-265.
85. Kilaru P and BAKRIS GL. Renal mortality associated with NIDDM **J Diab Compl** 1997;11:104-111.
86. Mangrum and BAKRIS GL. Predictors of renal and cardiovascular mortality: A brief overview of microalbuminuria and insulin resistance. **J Diab.Compl** 1997; 11(6):352-357
87. BAKRIS GL and Smith AC. Antihypertensive therapy and treatment of diabetic nephropathy: prognostic implications **J Cardiovasc. Pharmacol** 1997;30 (Suppl 2):31-34
88. BAKRIS GL, Mangrum A, Copley JB, Vicknair N, Sadler R. Calcium channel or beta blockade on progression of diabetic renal disease in African-Americans **Hypertension** 1997;29:744-750
89. BAKRIS GL and White D. Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy **J Human Hypertens** 1997;11:35-38

90. Simeon G and BAKRIS GL. Socioeconomic impact of diabetic nephropathy: can we improve the outcome? **J. Hypertension** 1997;15(Suppl 2):S77-S82
91. BAKRIS GL, Burszty M, Gavras I, Bresnahan M, Gavras H. Role of vasopressin in essential hypertension: racial differences. **J. Hypertension** 1997;15:545-550
92. Silverman M, BAKRIS GL. Treatment of renal failure and blood pressure. **Cur Opin Nephrol and Hypertension** 1997;6:237-242.
93. Tarif N and BAKRIS GL Preservation of renal function: the spectrum of effects by calcium channel blockers. **Nephrol Dial Transpl** 1997;12:2244-2250
94. BAKRIS GL, Kusmirek SL, Smith AC, Gavras I, Gavras H. Calcium antagonism abolishes the antipressor action of vasopressin (V1) receptor antagonism. **Am J Hypertension** 1997;10(10):1153-1158
95. BAKRIS GL, Griffin KA, Picken MM, and Bidani AK. Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. **J Hypertension** 1997;15:1181-1185
96. Joint National Committee Report on the Diagnosis and Treatment of Hypertension (JNC VI) **Arch Intern Med** 1997;157:2413-2446
97. Tarif N and BAKRIS GL. Renal components of the hypertensive syndrome. **J Cardiovasc Risk** 1997;4(4):271-278
98. Tarif N and BAKRIS GL. Angiotensin II receptor blockade and progression of renal disease in nondiabetic patients. **Kidney Int** 1997; 52 (Suppl. 63): 67-70
99. Makrilakis K and BAKRIS GL. New therapeutic approaches to achieve the desired blood pressure goal. **Cardiovasc Rev. & Reports** 1997;18:10-16.
100. BAKRIS GL. Controversies in hypertension management: target blood pressure in diabetic subjects. **Diabetes Reviews International** 1998;7:2-5.
101. Makrilakis K and BAKRIS GL: Diabetic Hypertensives: improving their prognosis **Cardiovasc Pharmacol.** 1998;31(Suppl 2):S34-S40
102. BAKRIS GL. Progression of diabetic nephropathy: focus on arterial pressure level and methods of reduction. **Diabetes Res and Clin Pract**, 1998;39 (Suppl):35-42
103. Smith AC, Toto R, BAKRIS GL Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy **Kidney Int.** 1998;54:889-896
104. BAKRIS GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. **Kidney Int.** 1998;54:1283-1289
105. Villarosa I and BAKRIS GL The ABCD Trial in Perspective: An invited editorial. **J Human Hypertension** 1998;12:653-655
106. BAKRIS GL. The role of combination antihypertensive therapy in the progression of renal disease from hypertension: looking toward the next millennium. **Am J Hypertens** 1998;11 (Suppl.): 158-162
107. Rabelink TJ and BAKRIS GL The renin-angiotensin system and diabetic nephropathy: the endothelial connection **Min & Electrol Metab** 1998;24:381-388
108. Griffin KA, Picken MA, Bakris GL, Bidani AK. Class differences in the effects of calcium channel blockers in the rat remnant kidney model **Kidney Int.** 1999;55: 1849-1860
109. BAKRIS GL, Lass NA, Glock D. A role for dopamine-1 receptors in radiocontrast medium-induced reductions in renal hemodynamics. **Kidney Int.** 1999;56:206-210
110. BAKRIS GL, Weber MA, Black HR, Weir MR. Clinical efficacy and safety profiles of AT1 receptor antagonists. **Cardiovasc Reviews and Reports** 1999;20:77-100
111. Sheinfeld GR and BAKRIS GL Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. **Am J Hypertension** 1999;12:80S-85S.

112. Villarosa I, BAKRIS GL, Newer Approaches and Blood Pressure Goals for Treatment of Hypertension in Diabetes **J Cardiovasc. Pharmacol** 1999;34(Suppl. 3):S11-S16
113. BAKRIS GL. Maximizing Cardio-renal Benefits: Achieve Blood Pressure Goals. **J Clin. Hypertens**, 1999;1:141-148
114. BAKRIS GL and Weir MR. ACE Inhibitor associated elevations in serum creatinine: Is this a cause for concern? **Arch Intern Med**, 2000;160: 685-693
115. Swan S, Elliott WJ, BAKRIS GL Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives [an editorial] **J Clin Pharmacol** 2000;40:7-10.
116. Griffin KA, Picken MA, Bakris GL, Bidani AK. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation **Kidney Int.** 2000; 57: 1651-1661
117. BAKRIS GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J for the National Kidney Foundation Hypertension and diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: A Consensus Approach. **Am J Kidney Dis** 2000;36: 646-661
118. BAKRIS GL, Sowers JA, Epstein M, Williams M. Diabetic Hypertension: why is aggressive treatment essential? **Postgraduate Med** 2000;107:53-64
119. Elliott WJ, Maddy R, Toto R, BAKRIS GL. Diabetic Hypertension: barriers to effective control **Postgraduate Med** 2000;107:29-37
120. Sowers JR, Williams M , Epstein M , BAKRIS GL Diabetic Hypertension: strategies for treatment. **Postgraduate Med** 2000;107:47-60
121. Weir MR, Maibach EW, BAKRIS GL, Black HR, Chawla P, Messerli FH, Neutel JM, Weber MA Implications of a health lifestyle and medication analysis for improving hypertension control. **Arch Intern Med** 2000;160(4):481-490
122. Sowers JR and BAKRIS GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus [editorial]. **N Engl J Med** 2000;342:969-970
123. BAKRIS GL Salt intake and its impact on hypertension **Cardiovasc Rev & Reports** 2000;21: 176-180
124. BAKRIS GL, Whelton P, Weir M, Mimran A, Keane W, Schiffrin E for the Evaluation of Clinical Trial Endpoints in Chronic Renal Disease Group. The Future of Clinical Trials in Chronic Renal Disease: Outcome of a NIH/FDA/Physician Specialist Conference **J Clin Pharmacol** 2000;40: 815-825
125. Koshy S, BAKRIS GL Therapeutic Approaches to Achieve Desired Blood Pressure Goals: Focus on Calcium Channel Blockers **Cardiovasc Drugs and Therapy** 2000;14:295-301
126. Odama U and BAKRIS GL Target organ Damage in Hypertension. **J Clin Hypertens** 2000;2: 312-318
127. Basta E and BAKRIS GL Evolution of drugs that preserve renal function. **J Clin Pharmacol.** 2000 Sep;40(9):978-89. Review.
128. BAKRIS GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, Agarwal R, and Catanzaro D, for the VAL-K study group. ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure. **Kidney Int** 2000;58:2084-2092
129. Vora JP, Ibrahim HAA and BAKRIS GL. Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. **J Hum Hypertens** 2000;14: 667-685
130. BAKRIS GL Lower blood pressure goals for patients with diabetes: The National Kidney Foundation Consensus Report. **J Clin Hypertension** 2000;2(6): 369-371

131. Smith AC, Fogelfeld L and BAKRIS GL. New therapies in diabetes-thiazolidinediones. **Emerging Drugs** 2000;5(4):441-456
132. BAKRIS GL, Gradman A, Reif M, Wofford M, Munger M, Harris, S, Vendetti J, Michelsen E, Wang R and the CLAIM study investigators. Antihypertensive efficacy of candesartan in comparison to losartan: The CLAIM trial. **J Clin Hypertens** 2001;3:16-21
133. Tarif N and BAKRIS GL The place of calcium channel blockers in the treatment of hypertension in diabetes. **Saudi J of Kidney Dis and Transpl** 2001; 13:43-49
134. BAKRIS GL Treatment of stage I hypertension and development of renal dysfunction. **J Hum Hypertens** 2001;15:81-84
135. Microalbuminuria: What is it and How should we be measuring it? **J Clin Hypertens (Greenwich)** 2001;3:99-102
136. Griffin KA, Picken M, BAKRIS GL, Bidani AK. Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model. **Hypertension** 2001; 37: 1268-127
137. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis :a randomized controlled trial. **JAMA**. 2001;285:2719-2728.
138. BAKRIS GL Angiotensin-converting enzyme inhibition to enhance vascular health-clinical and research models. **Am J Hypertens**. 2001 Aug;14(8 Pt 2): 264S-269S.
139. Brenner BM, Cooper ME, DeZeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, and Shahinfar S for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. **N Engl J Med** 2001;345:861-869.
140. Basta E and BAKRIS G. Choices and Goals in the Treatment of the Diabetic Hypertensive Patient. **Current Hypertension Reports** 2001;3:387-391
141. Garg J and BAKRIS GL Prevention and management of renal disease in the patient with diabetes mellitus. **Cardiovasc Reviews & Reports** 2001;22:718-728
142. BAKRIS GL A practical approach to achieving recommended blood pressure goals in diabetic patients. **Arch Intern Med** 2001;161:2661-2667
143. Griffin KA, Picken MM, BAKRIS G, Bidani AK. Relative antihypertensive and glomerulo-protective efficacies of enalapril and candesartan cilexetil in the remnant kidney model. **J Renin Angiotensin Aldosterone Syst**. 2001;2(1):191-195.
144. BAKRIS GL, Sica D, Ram V, Fagan T, Vaitkus PT, Anders RJ. A comparative trial of controlled-onset, extended-release verapamil, enalapril and losartan on blood pressure and heart rate changes. **Am J Hypertens** 2002;15:53-57
145. Sica DA, BAKRIS GL . Current concepts of pharmacotherapy in hypertension: Type 2 diabetes: RENAAL and IDNT-the emergence of new treatment options. **J Clin Hypertens (Greenwich)** 2002;4(1):52-57
146. Hogan TJ, Elliott WJ, Seto AH, Bakris GL. Antihypertensive Treatment with and without Benazepril in Patients with Chronic Renal Insufficiency: A US Economic Evaluation. **Pharmacoeconomics** 2002;20(1):37-47.

147. BAKRIS GL, Smith AC, Richardson DJ, Hung E, Preston R, Goldberg R, Epstein M. Impact of an ACE inhibitor and calcium antagonist on micro-albuminuria and lipid subfractions in type 2 diabetes: a randomized, multi-centre pilot study. **J Hum Hypertens**. 2002;16 (3):185-191.
148. Russo LM, BAKRIS GL and Comper WD-Renal handling of albumin: A critical review of basic concepts and perspective. **Am J Kidney Dis** 2002;39(5): 899-919
149. BAKRIS GL and Mensah GA. Pathogenesis and clinical physiology of hypertension. **Cardiology Clinics** 2002;20:195-206
150. Garg J, Messerli A, and BAKRIS GL Evaluation and treatment of patients with systemic hypertension **Circulation** 2002;105:2458-2461
151. Garg J, BAKRIS GL Angiotensin converting enzyme inhibitors or Angiotensin receptor blockers in nephropathy from type 2 diabetes. **Curr Hypertens Rep** 2002;4(3):185-190
152. Moser M, BAKRIS GL, Black H. Roundtable discussion: problems in the management of hypertension. **J Clin Hypertens** (Greenwich). 2002;4(3):207-213.
153. Garg J, BAKRIS GL: Treatment of hypertension in patients with renal disease. **Cardiovasc. Drugs Ther**. 2002;16:503-510
154. Garg J and BAKRIS GL Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease **J. Vasc Med** 2002 Feb;7(1):35-43.
155. BAKRIS GL and Sowers JR Microalbuminuria in Diabetes: Focus on Cardiovascular and Renal Risk Reduction. **Current Diabetes Reports** 2002;2(3): 258-262
156. BAKRIS GL, Calhoun D, Egan B, Hellmann C, Kingma I, Orlistat Improves Blood Pressure Control in Obese Subjects with Inadequately Controlled Hypertension. **J. Hypertension** 2002; 20:2257-2267
157. Wright, JT Jr., BAKRIS G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glasscock R, Hebert, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JT, and Rostand SG. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. **JAMA** 2002; 288; 2421-2431
158. Sowers, JR, Ferdinand, K, BAKRIS GL, and Douglas JG. Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome. **Postgrad.Med**. 2002;112 (4):24-30.
159. BAKRIS GL, Ferdinand KC, Douglas JG, and Sowers JR. Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals. **Postgrad.Med**. 2002;112 (4):73-80.
160. Douglas JG, Ferdinand KC, BAKRIS GL, and Sowers JR. Barriers to blood pressure control in African Americans. Overcoming obstacles is challenging, but target goals can be attained. **Postgrad. Med**. 2002;112 (4):51-62.
161. BAKRIS GL. Hypertension and diabetes: family physicians' pivotal role. **Am. Fam. Physician** 2002;66 (7):1151-1152 [Invited Editorial].
162. BAKRIS GL and Weir M. ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence. **J.Clin.Hypertens**.(Greenwich.) 2002;4(6): 420-423.
163. Kaperonis N and BAKRIS GL. Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans. **Curr. Opin. Nephrol. Hypertens**. 2003;12 (1):79-84.
164. BAKRIS GL, Viberti G, Weston WM, Heise M, Porter, LE and Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. **J Hum Hypertens** 2003;17:7-12
165. Giles TD, BAKRIS GL, Smith DHG, Davidai, Weber MA. Defining the Antihypertensive Properties of The Angiotensin Receptor Blocker Telmisartan by a Practice-Based Clinical Trial. **Am J Hypertens** 2003;16:460-466

166. Chobanian, AV, BAKRIS, GL, Black, HR, Cushman, WC, Green, LA, Izzo, JL Jr., Jones, DW, Materson, BJ, Oparil, S, Wright, JT Jr., and Roccella, EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. **JAMA** 2003;289:2560-2571
167. BAKRIS, GL and Sowers, JR. Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction. **Curr.Diab.Rep.** 2002;2 (3):258-262.
168. Douglas, J, BAKRIS, GL, Epstein, M, Ferdinand, KC, Ferrario, C, Flack, JM, Jamerson, KA, Jones, WE, Haywood, J, Maxey, R, Ofili, EO, Saunders, E, Schiffrin, EL, Sica, DA, Sowers, JR and Vidt, DG. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. **Arch Intern Med** 2003;163: 525-541.
169. Gassman, J.J.; Greene, T.; Wright, J.T., Jr.; Agodoa, L.; BAKRIS, G.; Beck, G.J.; Douglas, J.; Jamerson, K.; Lewis, J.; Kutner, M.; Randall, O.S.; Wang, S.R. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). **J Am Soc Nephrol** 2003;14:S154-S165.
170. Appel, L.J.; Middleton, J.; Miller, E.R., III; Lipkowitz, M.; Norris, K.; Agodoa, L.Y.; BAKRIS, G.; Douglas, J.G.; Charleston, J.; Gassman, J.; Greene, T.; Jamerson, K.; Kusek, J.W.; Lewis, J.A.; Phillips, R.A.; Rostand, S.G.; Wright, J.T. The rationale and design of the AASK cohort study. **J Am Soc Nephrol.** 2003;14:S166-S172
171. BAKRIS, G.L. Weir, M.R. for the SHIELD Investigators. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches **J Clin Hypertens** 2003;5:202-209
172. BAKRIS GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk, DJ, Brenner BM for the RENAAL Study Group. Effects of Blood Pressure Level on Progression of Diabetic Nephropathy. **Arch Intern Med** 2003;163:1555-1565
173. Trespalacios, F.C., Taylor, A.J., Agodoa, L.Y., BAKRIS, G.L. Abbott, K.C. Heart failure as a cause for hospitalization in chronic dialysis patients **Am J Kidney Dis** 2003;41:1267-1277
174. Weinberg MS, Kaperonis N, BAKRIS GL. How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? **Curr Hypertens Reports** 2003;5:418-425.
175. BAKRIS GL. Who should be treated with combination therapy as initial treatment for hypertension? **J.Clin.Hypertens.(Greenwich.)** 2003;5 (4 Suppl 3):21-28
176. BAKRIS GL. Achieving blood pressure goals: is fixed-dose combination therapy the answer? **J.Clin.Hypertens.(Greenwich.)** 2003;5 (4 Suppl 3):2-3
177. BAKRIS GL Role for beta blockers in the management of diabetic kidney disease **Am J Hypertens** 2003;16 (9) Pt.2:7-12
178. Abbott KC and BAKRIS GL Kidney and cardiovascular disease **Circulation** 2003;108: e114-e115
179. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Kowey P, Messerli FH, Mancina G, Cangiano JL, Garcia-Baretto D, Keltai M, Bristol HA, Kolb HR, Marks R and BAKRIS GL for the INVEST Investigators. Main outcomes from a randomized trial of a calcium antagonist vs. noncalcium antagonist blood pressure treatment strategy in patients with coronary artery disease: the International Verapamil-trandolapril Study (INVEST). **JAMA** 2003;290:2805-2816
180. Chobanian AV, BAKRIS GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr., and Roccella EJ. Seventh report of the Joint National Committee on

Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. **Hypertension**. 2003;42 (6):1206-1252

181. Garg J and Bakris GL. Are antihypertensive drugs used to maximally reduce cardiovascular risk in dialysis patients? **Am. J. Kidney. Dis**. 2003;42(6): 1301-1304.
182. BAKRIS GL. Hypertension and nephropathy. **Am J Med**. 2003;115:49S-54S
183. Weber MA, BAKRIS GL, Neutel JM, Davidai G, and Giles TD. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. **J Clin Hypertens (Greenwich)** 2003;5 (5):322-329.
184. Eknoyan G, Hostetter T, BAKRIS GL, Hebert L, Levey AS, Parving HH, Steffes MW, and Toto R. Proteinuria and other markers of chronic kidney disease: A position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). **Am.J.Kidney.Dis**. 2003;42 (4):617-622
185. Chua, DY and BAKRIS GL. Diabetes and chronic kidney disease: tragedy and challenge. **Blood.Purif**. 2004;22 (1):130-135
186. Abbott KA and BAKRIS, GL. What have we learned from the current trials? **Med. Clin. No. Am**. 2004;88 (1):189-207
187. Izhar M, Alausa T, Folker A, Hung E, and BAKRIS GL. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. **Hypertension** 2004;43 (3):573-577
188. BAKRIS GL. The importance of blood pressure control in the patient with diabetes. **Am. J. Med** 2004;116 Suppl 5A:30S-38S
189. Mangrum AL and BAKRIS GL. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: Safety issues. **Seminars Nephrol**. 2004;24 (2): 168-175
190. Abbott K, Basta E, and BAKRIS GL. Blood pressure control and nephroprotection in diabetes. **J.Clin.Pharmacol**. 2004;44 (4):431-438.
191. Davidson MB, Bazargan M, BAKRIS G, Harmel A, Peters G, Campese V, and Basta E. ImmunoDip: An Improved Screening Method for Microalbuminuria. **Am J Nephrol** 2004; 24 (3):284-288
192. Gashti CN and BAKRIS GL The role of calcium antagonists in chronic kidney disease. **Curr Opin in Nephrol and Hypertens** 2004;13:155-161
193. BAKRIS GL, Weir MR, Secic M, Campbell B, and Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. **Kidney Int**. 2004;65 (6):1991-2002
194. BAKRIS GL and Sowers JR. When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk. **Hypertension** 2004;43: 941-942
195. Chua DY and BAKRIS GL. Is proteinuria a plausible target of therapy? **Curr Hypertens Rep** 2004;6 (3):177-181
196. Khosla N, Hart P, and BAKRIS GL. Management of hypertension in the cardiometabolic syndrome and diabetes. **Curr.Diab.Rep**.2004; 4 (3):199-205
197. Ruilope LM, Usan L, Segura J, and BAKRIS GL. Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResion Arterial en Diabeticos tipo Dos) study. **J. Hypertens** 2004;22 (1):217-222
198. Hart, PD and BAKRIS GL. Hypertension control rates: time for translation of guidelines into clinical practice. **Am J Med** 2004;117 (1):62-64.
199. BAKRIS GL and Toto R. Guest editorial: Hypertension and kidney disease. **Adv. Chronic Kidney Dis**. 2004;11 (2):114-115.

200. Chua DY and BAKRIS GL. Clinical implications of blockade of the renin-angiotensin system in management of hypertension. **Contrib Nephrol** 2004;143: 105-116
201. Chrysant SG and BAKRIS GL Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. **Am J Hypertens** 2004;17 (7):590-596
202. BAKRIS GL Clinical importance of microalbuminuria in diabetes and hypertension. **Curr Hypertens Rep.** 2004; 6 (5):352-356
203. Jamerson, KA, BAKRIS GL, Wun CC, Dahlof B, Lefkowitz M, Manfreda S, Pitt B, Velazquez EJ, and Weber MA. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. **Am. J Hypertens** 2004;17 (9):793-801
204. BAKRIS GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, Cooper-DeHoff R, Pepine CJ. For the INVEST investigators. Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study. **Hypertension** 2004;44:637-642
205. BAKRIS GL, Toto RD, and McCullough PA. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. **J Hum.Hypertens.** 2004;19:139-144
206. BAKRIS GL Inclusion of albuminuria in hypertension and heart guidelines **Kidney Int** 2004; 92:S124-S125
207. BAKRIS GL; Fonseca V; Katholi RE; McGill JB; Messerli FH; Phillips RA; Raskin P; Wright JT, Jr; Oakes R;; Lukas M; Anderson KM; Bell DSH for the GEMINI Investigators Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension: A Randomized Controlled Trial **JAMA.** 2004; 292:2227-2236
208. Busby DE and BAKRIS GL. Comparison of commonly used assays for the detection of microalbuminuria. **J Clin Hypertens** (Greenwich.) 2004;6 (11 Suppl 3):8-12
209. BAKRIS GL. Implications of albuminuria on kidney disease progression. **J Clin Hypertens** (Greenwich.) 2004;6 (11 Suppl 3):18-22
210. BAKRIS GL, Bank AJ, Kass DA, Neutel JM, Preston RA, and Oparil S. Advanced glycation end-product cross-link breakers A novel approach to cardiovascular pathologies related to the aging process. **Am J Hypertens** 2004;17 (12 Pt 2):S23-S30
211. Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, and BAKRIS GL. beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. **Arch. Intern. Med** 2004;164 (22):2465-2471
212. McFarlane SI, Castro J., Kaur J, Shin JJ, Kelling D, Jr., Farag A, Simon N, El-Atat F, Sacerdote A, Basta E, Flack J, BAKRIS G, and Sowers JR. Control of blood pressure and other cardiovascular risk factors at different practice settings:outcomes of care provided to diabetic women compared to men. **J. Clin. Hypertens. (Greenwich)** 2005;7 (2):73-80
213. El-Achkar TM, Ohmit SE, McCullough PA, Crook ED, Brown WW, Grimm R, BAKRIS GL, Keane WF, and Flack JM. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. **Kidney Int** 2005; 67:1483-1488
214. BAKRIS GL, Bell DS, Fonseca V, Katholi R, McGill J, Phillips R, Raskin P, Wright, JT Jr., Iyengar M, Holeslaw T, and Anderson KM. The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial **J. Diabetes & Complications** 2005;19 (2):74-79

215. Khosla N, Chua DY, Elliott WJ, and BAKRIS GL Comparison of Thiazide Diuretics on Blood Pressure Reduction in Patients Not At Goal Blood Pressure **J Clin Hypertens, Greenwich** 2005;7(6):354-356
216. Winer N, Folker A, Murphy JA, Hung E, Bard M, Perkelvald A, Sowers, JR and BAKRIS GL. Effects of fixed-dose ACE inhibitor/calcium channel blocker combination therapy vs. ACE inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes. **Preventive Cardiology** 2005;8(2):87-92
217. BAKRIS GL. Protecting renal function in the hypertensive patient: Clinical guidelines. **Am J Hypertens.** 2005;18 (4 Suppl):112-119
218. BAKRIS GL. Preventing hypertensive kidney disease: the critical role of combination therapy. **Am J Hypertens** 2005;18 (4 Suppl):93-94.
219. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand S, Miller ER, Smith W, BAKRIS GL, and for the AASK investigators. Magnitude of Proteinuria Reduction Predicts Risk of End-Stage Renal Disease: Results of the AASK trial. **Arch. Intern Med** 2005;165:947-953
220. Preston RA, White WB, Pitt B, BAKRIS G, Norris PM, and Hanes V. Effects of Drospirenone/17-beta Estradiol on Blood Pressure and Potassium Balance in Hypertensive Postmenopausal Women. **Am J .Hypertens.** 2005;18 (6):797-804
221. White WB, Weber MA, Davidai G, Neutel JM, BAKRIS GL, and Giles T. Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. **Blood Press Monit.**2005;10 (3):157-163.
222. Russo CJ, Melista E, Cui J, Destefano AL, BAKRIS GL, Manolis AJ, Gavras H, and Baldwin CT. Association of NEDD4L Ubiquitin Ligase With Essential Hypertension. **Hypertension** 2005;46: 488-491
223. Garg JP, Ellis R, Elliott WJ, Hasabou N, Chua D, Chertow GM, and Bakris GL. Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study. **Am. J. Nephrol.** 2005;25 (4):393-399
224. BAKRIS GL. Proteinuria: a Link to Understanding Changes in Vascular Compliance? **Hypertension** 2005;46:473-474
225. Ruilope LM, Rosei EA, BAKRIS GL, Mancia G, Poulter NR, Taddei S, Unger T, Volpe M, Waeber B, and Zannad F. Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection. **Blood Press** 2005;14 (4):196-209
226. Nathan S, Pepine CJ, and BAKRIS GL. Calcium Antagonists. Effects on Cardio-Renal Risk in Hypertensive Patients. **Hypertension,** 2005;46:637-642
227. Mishra SI, Jones-Burton C, Fink C, Brown J, BAKRIS GL, and Weir MR. Does dietary salt increase the risk for progression of kidney disease? **Curr.Hypertens.Rep.** 2005;7(5): 385-391.
228. BAKRIS GL. Combination drug treatment for hypertension with nondiabetic renal disease. **Curr.Hypertens.Rep.** 2005;7 (5):358-359.
229. BAKRIS GL. Proteinuria and blood pressure reduction: are they of equal importance to preserve kidney function? **Curr. Hypertens. Rep.** 2005;7 (5):357-358.
230. Tuttle KR, BAKRIS GL, Toto RD, McGill JB, Hu K, and Anderson PW. The effect of ruboxistaurin on nephropathy in type 2 diabetes. **Diabetes Care** 2005: 28 (11): 2686-2690
231. BAKRIS GL, Smith DH, Giles TD, White WB, Davidai G, and Weber MA. Comparative antihypertensive efficacy of Angiotensin receptor blocker-based treatment in African-American and white patients. **J. Clin. Hypertens.** (Greenwich.) 2005;7 (10):587-595.

232. BAKRIS GL, Fonseca V, Katholi RE, McGill JB, Messerli F, Phillips RA, Raskin P, Wright JT, Jr., Waterhouse B, Lukas MA, Anderson KM, and Bell DS. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. **Hypertension** 2005;46(6): 1309-1315.
233. White WB, Giles T, BAKRIS GL, Neutel JM, Davidai G, and Weber MA. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. **Am. Heart J** 2006;151 (1):176-184
234. Sarafidis PA and BAKRIS GL. Level of kidney function determines cardiovascular fate after coronary bypass graft surgery. **Circulation** 2006;113 (8):1046-1047
235. Khosla N and BAKRIS GL Lessons learned from recent hypertension trials about kidney disease. **Clin J Am Soc Nephrol** 2006;1:229-235
236. Bogojevic Z and BAKRIS GL Albuminuria and Cardiovascular Risk **Heart Failure Clinics** 2006;2:53-59.
237. Ofili EO, Ferdinand KC, Saunders E, Neutel JM, BAKRIS GL, Cushman WC, Sowers JR, and Weber MA. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. **J Natl.Med.Assoc.** 2006;98 (4): 618-626.
238. Weber MA, White WB, Giles TD, BAKRIS GL, Neutel JM, Smith DH, and Davidai G. An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements. **J Clin Hypertens (Greenwich.)** 2006;8 (4):241-250.
239. Sarafidis PA and BAKRIS GL. Are Beta blockers passe for the treatment of hypertension? **J Clin Hypertens (Greenwich.)** 2006;8 (4):239-240.
240. Milchak JL, Carter BL, Ardery G, Black HR, BAKRIS GL, Jones DW, and Kreiter CD. Development of explicit criteria to measure adherence to hypertension guidelines. **J Hum Hypertens**, 2006;20:426-433
241. Sarafidis PA, McFarlane SI, and BAKRIS GL. Gender Disparity in Outcomes of Care and Management for Diabetes and the Metabolic Syndrome **Current Diabetes Rep.** 2006;6:219-224.
242. Sarafidis PA and BAKRIS GL Antihypertensive therapy and the risk of new-onset diabetes. **Diabetes Care** 2006;29:1167-1169
243. Saradifis PA and BAKRIS GL. Do the metabolic effects of Beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? **J Clin Hypertens (Greenwich.)** 2006;8 (5):351-356244.
244. Zillich AJ, Garg J, BAKRIS GL, Carter BL. Thiazide Diuretics, Potassium, and the Development of Diabetes: A Critical Review. **Hypertension** 2006;48:219-224
245. Lim HS, MacFadyen RJ, BAKRIS G, and Lip GY. The role of hyperglycaemia and the hypercoagulable state in the pathogenesis of cardiovascular events in diabetes mellitus:implications for hypertension management. **Curr.Pharm.Des** 2006;12 (13): 1567-1579.
246. Sowers JR, Neutel JM, Saunders E, BAKRIS GL, Cushman WC, Ferdinand KC, Ofili EO, and Weber MA. Antihypertensive Efficacy of Irbesartan/HCTZ in Men and Women With the Metabolic Syndrome and Type 2 Diabetes.**J. Clin. Hypertens (Greenwich.)** 2006;8:470-480.
247. Sarafidis PA and BAKRIS GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. **QJM.** 2006;99 (7):431-436.
248. Jones-Burton, CJ Mishra SI, Fink JC, Brown J, Gossa W, BAKRIS GL, and Weir MR. An in depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. **Am. J. Nephrol** 2006;26 (3):268-275

249. Messerli FH, BAKRIS GL, Ferrera D, Houston MC, Petrella RJ, Flack JM, Lee W Sun E, and Neutel JM. Efficacy and Safety of Coadministered Amlodipine and Atorvastatin in Patients With Hypertension and Dyslipidemia: Results of the AVALON Trial. **J.Clin.Hypertens. (Greenwich)** 2006;8 (8):571-581.
250. Khosla N, Sarafidis PA, and BAKRIS GL. Microalbuminuria. **Clin.Lab Med.** 2006; 26 (3):635-653.
251. Sarafidis PA and BAKRIS GL. Protection of the kidney by thiazolidine-diones: An assessment from bench to bedside. **Kidney Int.**, 2006;70:1223-1224
252. Bakris G. Clinical trials report. **Curr.Hypertens.Rep.** 2006;8 (5):395-397.
253. BAKRIS GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, Raz I, Voors A, Dechamplain J, and Weber MA. Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial. **J Human Hypertens** 2006;20 (9):693-700
254. Cooper-DeHoff R, Cohen JD, BAKRIS GL, Messerli FH, Erdine S, Hewkin AC, Kupfer S, and Pepine CJ. Predictors of Development of Diabetes Mellitus in Patients With Coronary Artery Disease Taking Antihypertensive Medications (Findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). **Am.J.Cardiol.** 2006;98 (7):890-894
255. BAKRIS GL, Tarka EA, Waterhouse B, Goulding MR, Madan A, and Anderson KM. Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. **Am J Cardiol.** 2006; 98 (7A):46-52.
256. Weber MA, Sica DA, Tarka EA, Iyengar M, Fleck R, and BAKRIS GL. Controlled-release carvedilol in the treatment of essential hypertension. **Am.J.Cardiol.** 2006;98 (7A):32-38.
257. Sarafidis PA and BAKRIS GL. Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance? **J.Hum. Hypertens.**, 2006.-electronic
258. BAKRIS GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, and Porter LE. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. **J. Hypertens.** 2006;24 (10):2047-2055.
259. BAKRIS GL, Hart PD, Ritz E Beta blockers in the management of chronic kidney disease **Kidney Int** 2006;70:1905-1913
260. BAKRIS G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, and Sowers J. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. **Diabetes Care** 2006;29 (12):2592-2597.
261. Levin A, BAKRIS GL, Molitch M, Smulders M, Tian J, Williams LA, and Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. **Kidney Int.**, 2007;71:31-38
262. Sarafidis PA and BAKRIS GL. Insulin and endothelin: an interplay contributing to hypertension development? **J.Clin.Endocrinol.Metab**, 2006.-electronic
263. Whaley-Connell A, Pavey BS, Afroze A, and BAKRIS GL. Obesity and insulin resistance as risk factors for chronic kidney disease. **J Cardiometab.Syndr.** 2006;1(3):209-214.
264. Sarafidis PA and BAKRIS GL. Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents. **J.Hypertens.** 2007;25 (1):249-252.
265. Weber MA, BAKRIS GL, Tarka EA, Iyengar M, Fleck R, and Sica DA. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. **J.Clin.Hypertens.(Greenwich.)** 2006;8 (12):840-849.
266. Sarafidis PA and BAKRIS GL. Are antihypertensive drugs associated with an increased risk of incident type 2 diabetes? **Nat.Clin.Pract.Endocrinol.Metab** 2007;3 (1):8-9.

267. Sarafidis PA, Khosla N, and BAKRIS GL. Antihypertensive therapy in the presence of proteinuria. **Am.J.Kidney Dis** 2007; 49 (1):12-26.
268. Buse JB, Ginsberg HN, BAKRIS GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, and Stone NJ. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. **Diabetes Care** 2007;30 (1):162-172.
269. BAKRIS GL, Dickholtz M Sr., Meyer PM, Kravitz G, Avery E, Miller M, Brown J, Woodfield C, and Bell B. Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: a pilot study. **J. Hum. Hypertens** 2007;21:347-352
270. Gilbert, RE, Kim SA, Tuttle KR, BAKRIS GL, Toto RD, McGill JB, Haney DJ, Kelly DJ, and Anderson PW. Effect of Ruboxistaurin on Urinary Transforming Growth Factor- β in Patients with Diabetic Nephropathy and Type 2 Diabetes. **Diabetes Care** 2007;30:995-996
271. Robinson JG, BAKRIS G, Torner J, Stone NJ, and Wallace R. Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly? **Stroke** 2007;38:441-450
272. Sarafidis PA and BAKRIS GL. The antinatriuretic effect of insulin: An Unappreciated Mechanism for Hypertension Associated with Insulin Resistance **Am J Nephrol** 2007;27:44-54
273. BAKRIS, GL, Weir MR, and Black HR. Improving blood pressure control rates: is there more we can do? **J.Clin.Hypertens.(Greenwich.)** 2007;9 (2):134-142
274. Ahmed A, Rich MW, Sanders PW, Perry JG, BAKRIS GL, Zile MR, Love TE, Aban IB, and Shlipak MG. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. **Am.J.Cardiol.** 2007;99 (3):393-398.
275. Chugh A and BAKRIS GL. Microalbuminuria: what is it? Why is it important? What should be done about it? An update. **J Clin.Hypertens. (Greenwich)** 2007;9 (3):196-200
276. BAKRIS GL, Weir MR, and Black HR. Improving blood pressure control rates: is there more we can do? **J Clin.Hypertens.(Greenwich.)** 2007;9 (2):134-142.
277. McGill JB, BAKRIS GL, Fonseca V, Raskin P, Messerli FH, Phillips RA, Katholi RE, Wright JT, Jr., Iyengar M, Anderson KM, Lukas MA, Dalal MR, and Bell DS. Beta-blocker use and diabetes symptom score: results from the GEMINI study. **Diabetes Obes.Metab** 2007;9 (3):408-417
278. Weber MA, BAKRIS GL, Dahlof B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Weir M, Kjeldsen S, Massie B, Nesbitt S, Ofili E, Jamerson K, and F. T. Investigators. Baseline characteristics in the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk. **Blood Press** 2007;16 (1):13-19
279. Smith TR, Philipp T, Vaisse B, BAKRIS GL, Wernsing M, Yen J, and Glazer R. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. **J Clin.Hypertens (Greenwich.)** 2007;9 (5):355-364.
280. BAKRIS GL. ACE Inhibitors and ARBs: Are They Better Than Other Agents to Slow Nephropathy Progression? **J Clin.Hypertens (Greenwich.)** 2007;9 (6):413-415.
281. Sarafidis PA, McFarlane SI, and BAKRIS GL. Antihypertensive Agents, Insulin Sensitivity, and New-onset Diabetes. **Curr.Diab.Rep.** 2007;7 (3):191-199.
282. Sarafidis PA, Lasaridis AN, Nilsson PM, Pikilidou MI, Stafilas PC, Kanaki A, Kazakos K, Yovos J, and BAKRIS GL. Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. **J Hum.Hypertens.**, 2007;21:709-716

283. Fonseca V, BAKRIS GL, Bell DS, McGill JB, Raskin P, Messerli FH, Phillips RA, Katholi RE, Wright JT, Jr., Waterhouse B, Lukas MA, and Anderson KM. Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. **Diabet.Med.**, 2007;24:759-763
284. McCullough PA, Jurkowitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, Chen SC, Li S, Singh A, Norris KC, Klag MJ, and BAKRIS GL. Independent Components of Chronic Kidney Disease as a Cardiovascular Risk State: Results From the Kidney Early Evaluation Program (KEEP). **Arch.Intern.Med.** 2007;167 (11):1122-1129.
285. Jamerson K, BAKRIS GL, Dahlof B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen SE, Cushman W, Papademetriou V, and Weber M. Exceptional early blood pressure control rates: The ACCOMPLISH trial. **Blood Press** 2007;16 (2):80-86.
286. Ruilope L, Kjeldsen SE, Sierra A. de la, Mancía G, Ruggenenti P, Stergiou GS, BAKRIS GL, and Giles TD. The kidney and cardiovascular risk - Implications for management: A consensus statement from the European Society of Hypertension. **Blood Press** 2007;16 (2):72-79.
287. Mancía G, Messerli F, Bakris G, Zhou Q, Champion A, and Pepine CJ. Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study. **Hypertension**, 2007-electronic.
288. BAKRIS GL and E. R. Gonzalez. Case study: the link between hypertension and diabetes. **J Manag.Care Pharm.** 2007;13 (5):17-19.
289. BAKRIS GL. Pharmacological augmentation of endothelium-derived nitric oxide synthesis. **J Manag.Care Pharm.** 2007;13 (5):9-12.
290. Messerli FH, Bell DS, Fonseca V, Katholi RE, McGill JB, Phillips RA, Raskin P, Wright, JT Jr., Bangalore S, Holdbrook FK, Lukas MA, Anderson KM, and BAKRIS GL. Body weight changes with beta-blocker use: results from GEMINI. **Am J Med.** 2007;120 (7):610-615.
291. BAKRIS GL. Protein kinase C-beta inhibition: a promise not yet fulfilled. **Clin J Am Soc Nephrol** 2007; 2 (4):619-620
292. Sowers JR, BAKRIS GL, Black HR, and Giles TD. The cardiometabolic syndrome and calcium channel blocker combination drugs. **J Cardiometab.Syndr.** 2007;2 (3):207-212.
293. Chugh A and BAKRIS GL. Pulse pressure and arterial stiffness: an emerging renal risk predictor? **J Hypertens** 2007;25 (9):1796-1797.
294. Bhatnagar V, O'Connor DT, Schork NJ, Salem RM, Nievergelt CM, Rana BK, Smith DW, BAKRIS GL, Middleton JP, Norris KC, Wright JT, Cheek D, Hiremath L, Contreras G, Appel LJ, and Lipkowitz MS. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. **J Hypertens** 2007;25 (10):2082-2092.
295. Hart PD and BAKRIS GL. Should beta-Blockers Be Used to Control Hypertension in People With Chronic Kidney Disease? **Semin. Nephrol** 2007;27 (5):555-564.
296. Black HR, BAKRIS GL, Weber MA, Weiss R, Shahawy ME, Marple R, Tannoury G, Linas S, Wiens BL, Linseman JV, Roden R, and Gerber MJ. Efficacy and Safety of Darusentan in Patients With Resistant Hypertension: Results From a Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study. **J Clin.Hypertens (Greenwich.)** 2007;9 (10):760-769.

ABSTRACTS (over 290-not listed)

INVITED BOOK CHAPTERS

1. BAKRIS GL, Frohlich ED: Hypertension in the elderly. IN: Current Therapy Cardiovascular Disease. (Hurst JW ed) B. C. Decker, Inc Philadelphia PA, 1991, pp 315-318.
2. BAKRIS GL, and Frohlich ED: Evolution of antihypertensive therapy in America. IN: An Era in Cardiovascular Medicine. (Knoebel SB and Dack S, eds) Elsevier Publishing, New York 1991, pp 71-84.
3. Murphy MB, BAKRIS GL: Oxyphenphylline. IN: Therapeutic Drugs: (Dollery C, et al, eds) Churchill Livingstone, United Kingdom, 1992 (vol 2):pp O50-O52.
4. BAKRIS GL, Frohlich ED: Essential hypertension in the elderly: rationale for therapy. IN: Hypertension and Renal Disease in the Elderly (Martinez -Maldonado M, et al, eds) Blackwell Scientific Publications, Boston, 1992;Chapter 9, pp 127-143.
5. Slataper R and BAKRIS GL: Secondary hypertension. IN: Difficult Diagnosis II (Taylor, R, ed) W.B. Saunders and Co. Philadelphia, 2nd edition, 1992, pp. 403-412.
6. BAKRIS GL: An approach to the hypertensive diabetic patient: emphasis on renal preservation. IN: Calcium Antagonists in Clinical Medicine, (Epstein M, ed), Hanley and Belfus Publishers, Philadelphia, 1992, chapter 17: pp. 326-352.
7. BAKRIS GL: Nephrotoxicity of radiocontrast medium. IN: Toxicology of the Kidney. (Goldstein R & Hook JB, eds), Raven Press, New York, 2nd ed, 1993: pp 361-389.
8. BAKRIS GL, Gavras H: Renin in clinical renal failure, acute and chronic including treatment. IN: The Renin-Angiotensin System in Man (Robertson J and Nicholls G, eds), Gower Med. Publishing, London,1993, Volume 2, Chp. 56: pp 1-14
9. BAKRIS GL,Slataper R: Renovascular Diseases. IN: Textbook of Internal Medicine (Stein JH, et al, eds), Mosby Press, St. Louis, 1993, 4th ed. chp. 362, pp.2774-2777
10. Stein JH and BAKRIS GL: Normal Renal Physiology. IN: Textbook of Internal Medicine (Stein JH, et.al., eds), Mosby Press, St. Louis,1993, 4th ed. chp 338,pp.2572-2579.
11. BAKRIS, GL: Hypertension IN: Internal Medicine: Diagnosis and Treatment (ed.) Stein JH, Appleton and Lange Pub., Conn. 1993, 3rd edition pp. 171-187.
12. Nachoum-Burgess D and BAKRIS, GL Aspects of Renal Medicine. IN: Internal Medicine: Diagnosis and Treatment. (ed) Stein JH, Appleton and Lange Pub., Conn. 1993, 3rd edition pp. 129-170.
13. BAKRIS, GL. Drug dosage adjustment in renal failure. IN: Internal Medicine: Diagnosis and Treatment. (ed) Stein JH, Appleton and Lange Pub. Conn., 1993, 3rd edition pp.598-620
14. BAKRIS, GL. Treatment of Hypertensive Patients with Diabetic Nephropathy. In Izzo J and Black HR (eds.)Am Heart Assoc. Hypertension Primer 1993 Dallas, TX, pp.357-360
15. Paradiso G, BAKRIS GL and Stein JH: The kidney in heart failure. IN: Heart Failure (McCall D and Rahimtoola S, eds), Current Topic In Cardiology Series. Chapman & Hall, New York, 1995, 1st ed., chp 8, pp.135-158
16. BAKRIS GL and Stein JH: Extracellular Fluid Balance and Sodium Homeostasis in Man. IN: Fluid and Electrolytes. (DeFronzo R and Arieff A, eds), 2nd Ed. Churchill Livingstone, New York, 1995, pp.29-50.
17. BAKRIS GL, Mehler P, and Schrier R. Hypertension and Diabetes. IN Schrier RW and Gottschalk CW (eds.) Diseases of the Kidney 6th ed., Little Brown and Company, 1996, pp.1455-1464.
18. BAKRIS GL, Walsh MF, Sowers JR. Endothelium/mesangium interactions : Role of insulin-like growth factors . IN: Endocrinology of the Vasculature (Sowers JR, ed). Humana Press Inc. New Jersey, 1996, pp.341-356.
19. Weir MR, BAKRIS GL, Toto RD, Flack JM, Williams B, Neutal JM. Hypertension section IN: Gonick H (ed) Current Nephrology Vol. 19 1996 pp.203-241

20. Yi J and BAKRIS GL. Pheochromocytoma. In Current Diagnosis 9, WB Saunders, New York, 1997, pp. 794-798
21. BAKRIS GL. The pathogenesis and prevention of radiocontrast-induced renal dysfunction IN: Comprehensive Toxicology (Sipes G, McQueen CA, Gandolfi AJ eds), Vol. 7[Renal Toxicology], Elsevier Scientific Ltd, London, 1997, pp. 547-565.
22. BAKRIS GL. Combination therapy for hypertension and renal disease in diabetes. In Mogensen CE (ed.) The Kidney and Hypertension in Diabetes Mellitus 3rd ED. Kluwer Academic, Boston, 1997, pp.561-568.
23. Weir MR, Bakris GL, Toto RD, Flack JM, Bravo M. Hypertension IN: Gonick H (ed) Current Nephrology Mosby-Year Books 1997;20:209-241.
24. Kilaru PK and Bakris GL. Calcium channel blockade and/or ACE inhibition in diabetic hypertensive nephropathy. IN: Combination Drug Therapy for Hypertension Opie LH and Messerli F, eds), Lippincott-Raven Publ., Philadelphia, 1997, pp.123-138.
25. Stein JH and BAKRIS GL: Principles of renal physiology. IN: Textbook of Internal Med (Stein JH, et al, eds), 5th ed. Mosby Press, St. Louis, 1998, pp.736-741
26. BAKRIS GL, Kusmirek SL: Renovascular Diseases. IN: Textbook of Internal Med. (Stein JH, et al, eds), 5th ed. Mosby Press, St. Louis, 1998, pp. 893-897.
27. Makrilakis C and BAKRIS GL. Calcium Channel Blockers:Are they created equal with regard to slowing progression of diabetic nephropathy. IN: Calcium Antagonists in Clinical Medicine, (Epstein M, ed), 2nd ed. 1998, Hanley and Belfus Publishers, Philadelphia, , pp. 273-290
28. Makrilakis K and BAKRIS GL. Effects of diabetes and hypertension on the aging kidney. In: Barbagallo M, Licata G and Sowers JR (eds) Recent Advances in Geriatrics. 1998, Plenum Press, New York pp. 83-90
29. Villarosa IP and BAKRIS GL. Combination therapy for hypertension and renal disease in diabetes. In Mogensen CE (ed.) The Kidney and Hypertension in Diabetes Mellitus 4th ed. Kluwer Academic, Boston, 1998, pp.569-579.
30. BAKRIS GL, Lash J and Kochar. Renal Diseases. In Kutty K and Kochar (eds) Kochar's Concise Textbook of Medicine. Williams and Wilkens, Baltimore, 3rd Edition, 1998, pp.674-696.
31. BAKRIS, GL. Treatment of Hypertensive Patients with Diabetic Nephropathy. In Izzo J and Black HR (eds.) Am Heart Assoc. Hypertension Primer 2nd ed. Lippincott, Raven Press, 1999
32. BAKRIS GL. The Kidney in Hypertension. IN: Messerli FH (ed). The ABCs of Hypertension. 2nd ed., Lippincott, Williams and Wilkens, Philadelphia 2000, pp.45-54
33. Johnson RJ, Kurokawa K, BAKRIS GL. Pathogenesis and clinical course of essential hypertension. IN: Johnson R and Freehally J (eds.) Principles of Nephrology Mosby & Co. London, 2000, pp. 38.1-12
34. Tarif N and BAKRIS GL. Pharmacologic treatment of essential hypertension. IN: Johnson R and Freehally J (eds.) Principles of Nephrology Mosby & Co. London, 2000 pp. 40.1-12
35. Villarosa I and BAKRIS GL. Antihypertensive treatment in type 2 diabetes with nephropathy. IN: Ritz E and Fliser D (eds.) Nephropathy in Type II Diabetes. Oxford University Press, London, 1999, pp. 111-136
36. Villirosa I and BAKRIS GL Treatment of hypertension in diabetes. IN Oparil S and Weber M (eds.) Hypertension: A Companion to Brenner & Rector's- The Kidney. W.B. Saunders & Co. New York, 2000, pp. 518-523
37. Yi J and BAKRIS GL Microalbuminuria in Atherosclerotic Vascular Disease. In: Loscalzo J and London G (eds.) Cardiovascular Disease in End-Stage Renal Failure, Oxford University Press, London, UK 2000 pp. 229-243
38. Odama U, Tarif N, BAKRIS GL. Hypertension. IN: Massry SG and Glasscock RJ (eds.) Textbook of Nephrology, 4th ed. Lippincott, Williams and Wilkins, Philadelphia 2001 Chp.33, p.550-554

39. BAKRIS GL. Clinical aspects of essential hypertension and its management. IN: Massry SG and Glasscock RJ (eds.) Textbook of Nephrology, 4th ed. Lippincott, Williams and Wilkins, Philadelphia. 2001 Chp. 61 (part 1), pp. 1141-1156
40. BAKRIS GL Chronic Renal Failure. In Crawford M and DiMarco J (eds.) International Textbook of Cardiology Mosby & Co. 2001, Section 8, pp. 1.1-1.12.
41. Black HR, BAKRIS GL, Elliott WJ. Hypertension: Epidemiology, Pathophysiology, Diagnosis and Treatment IN: Fuster V, Alexander W, O'Rourke R et.al (eds.) Hurst's The Heart. McGraw-Hill, New York, 2001 pp.1553-1604.
42. BAKRIS GL. Prevention and management of renal disease in the patient with diabetes mellitus. IN: Giles T (ed.) Diabetes & Cardiovascular Disease: A Practical Primer LSU Press, New Orleans 2001, pp.139-159
43. Izhar M, BAKRIS GL. Treatment of hypertension in patients with renal disease. IN Antman E (ed.) Cardiovascular Therapeutics, WB Saunders Co. Philadelphia 2002, pp.797-806.
44. Izhar M, BAKRIS GL. Hypertension. IN: Rakel R, Bope E (eds.) Conn's Current Therapy. WB Saunders Co. Philadelphia 2002, pp. 319-330
45. Izhar M and BAKRIS GL. Calcium Channel Blockers: Are they created equal with regard to slowing progression of diabetic nephropathy. IN: Calcium Antagonists in Clinical Medicine, (Epstein M, ed), 3rd ed. 2002, Hanley and Belfus Pub, Philadelphia.
46. Abbott KC and BAKRIS GL. Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction. IN: Poulain D, Oliet S and Theodosis D (eds.) Progress in Brain Research vol. 139-Vasopressin and Oxytocin: From Genes to Clinical Applications Elsevier Press, Amsterdam, 2002, pp. 289-298
47. Izhar M and BAKRIS GL. The management of hypertension in diabetes: guidelines for blood pressure control. IN: Williams B (ed.) Hypertension in Diabetes, Dunitz & Co. London 2003, pp.253-266.
48. BAKRIS GL. Treatment of hypertension with chronic renal insufficiency and albuminuria. IN: Izzo JL and Black HR (eds.) Hypertension Primer Lippincott, Williams and Wilkins Philadelphia, 2003, 2nd ed., pp.473-476.
49. Garg J, Izhar M, Ellis R, BAKRIS GL. Pharmacologic treatment of hypertension. IN: Johnson R and Freehally J (eds.) Principles of Nephrology Mosby & Co. London, 2003 pp. 497-514
50. Kanellis J, BAKRIS GL, Kurokawa K and Johnson RJ. Pathogenesis of Clinical Course of Essential Hypertension. Principles of Nephrology, Mosby & Co. London, 2003 pp. 477-488.
51. Hart PD and BAKRIS GL Managing Hypertension in the Diabetic Patient. IN: Egan BM, Basile JN, and Lackland DT (eds.) Hot Topics in Hypertension Hanley and Belfus, Philadelphia, 2004, pp.249-252.
52. Elliott WJ, BAKRIS GL, Black HR. Hypertension: Epidemiology, Pathophysiology, Diagnosis and Treatment IN: Fuster V, Alexander W, O'Rourke R et.al (eds.) Hurst's The Heart. McGraw-Hill, New York, 2004 11th Ed. pg. 1531-1576.
53. BAKRIS GL, Tarif N and Black HR. Arterial Hypertension in Diabetes: Etiology and Treatment. IN: DeFronzo RA, Ferranninni E, Keen H and Zimmet P. International Textbook of Diabetes Mellitus. Wiley & Sons, London, 2004 chapter 83, pp.1473-1499.
54. Ellis R and BAKRIS GL . Concomitant therapy in hypertension. In Crawford M and DiMarco J (eds.) International Textbook of Cardiology Mosby & Co. 2004, pp.576-580.
55. Kasmirek SL, Efstratopoulos A, BAKRIS GL Pharmacologic Treatment. In Crawford M and DiMarco J (eds.) International Textbook of Cardiology Mosby & Co. 2004, pp.533-544.
56. Hart PD and BAKRIS GL Combination therapy for hypertension and renal disease in diabetes. In Mogensen CE (ed.) The Kidney and Hypertension in Diabetes Mellitus 6th Ed. Taylor and Francis, London, 2004, pp.767-784.

57. Chua DY and BAKRIS GL Hypertension. In Kirby RS, Carson CC, Kirby MG and Farah RN (eds.) Men's Health 2nd ed. Taylor and Francis, London, 2004, pp.89-100
58. Chua DY and BAKRIS GL. Clinical Implications of blockade of the renin-angiotensin system in management of hypertension. In Contributions to Nephrology series C. Ronco (ed.) volume 143, Suzuki H and Saruta T (Eds.) Kidney and Blood Pressure Regulation, Karger, Basel, Switzerland, 2004, pp. 105-116.
59. Hoelscher D and BAKRIS GL. Hypertension as a risk factor for vascular disease. IN Caralis D and Bakris GL (Ed.) Lower Extremity Arterial Disease, Humana Press. New York 2005
60. Rothschild S and BAKRIS GL. Diabetes as a risk factor for vascular disease. IN Caralis D and Bakris GL (Ed.) Lower Extremity Arterial Disease, Humana Press., New York, 2005
61. Basha BJ, BAKRIS GL, Sowers JR. Atherosclerotic vascular disease. IN: Caralis D and Bakris GL(ed) Lower Extremity Arterial Disease, Humana Press. New York 2005
62. Ashgar A and BAKRIS GL. Diagnosis and Treatment of Hypertension. In: Greenberg A, Schwab S (Eds). Primer of Renal Disease, Elsevier/Saunders, Philadelphia, 4th Ed. 2005, pp. 562-572
63. Kaperonis N, Krause M and BAKRIS GL The pathogenesis and prevention of radiocontrast medium induced renal dysfunction In: Toxicology of the Kidney 3rd Ed. Tarloff JB and Lash LH (eds.) CRC Press, Philadelphia, 2005, pp. 817-860
64. Chua D and BAKRIS GL Hypertension and kidney Disease. In: Hypertension, Weir MR (ed.) 2005, Am College of Physicians. pp. 137-146
65. Hart P and BAKRIS GL Hypertension and the Kidney In: The Year in Hypertension Brunner H (Ed.) vol. 6 2006 Oxford Press, London pg.57-72
66. Chua DCY and BAKRIS GL Diabetic Nephropathy. In: Clinical Diabetes Fonseca V. (Ed.) chapter 12, 2006 Saunders/Elsevier Press, Philadelphia pp.156-164
67. Sarafidis P and BAKRIS GL Microalbuminuria and chronic kidney disease as cardiovascular risk factors. Chapter 49, IN: Lip G and Hall J(Eds.) Comprehensive Hypertension Graphic World Pub., London, 2006
68. Khosla N and BAKRIS GL Treatment of hypertension in patients with renal disease. Chapter 35. IN: Antman E and Oparil S (Eds.) Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease, 3rd Ed., Elsevier Pub. Philadelphia, 2007, pp. 647-653.
69. Khosla N, Sarafidis P and BAKRIS GL. The presence of proteinuria and antihypertensive drug selection. IN: Bakris GL (Ed) Therapeutic Strategies in Hypertension. Clinical Pub. Oxford, England, 2006 pp. 27-40
70. Chugh A and BAKRIS GL. Treatment of hypertension with chronic renal insufficiency and albuminuria. IN: Sicca D, Izzo JL and Black HR (eds.) Hypertension Primer Lippincott, Williams and Wilkins Philadelphia, 2007, 3rd ed., In Press
71. Wynne K and BAKRIS GL. Control of blood glucose and insulin resistance. IN: Lip GYH and Hall JE. Comprehensive Hypertension, Mosby/Elsevier Press. London 2007, pp. 1105-1112.
72. Sarafidis PA and BAKRIS GL. Kidney Disease and Hypertension. IN: Lip GYH and Hall JE. Comprehensive Hypertension, Mosby/Elsevier Press. London 2007, pp. 607-620.

BOOK EDITOR

- Sobel B and BAKRIS GL. Hypertension: A Clinician's Guide to Diagnosis and Treatment. Sobel and Bakris (eds.) Hanley and Belfus, Philadelphia, 1st ed. 1995
- Sobel B and BAKRIS GL. Hypertension: A Clinician's Guide to Diagnosis and Treatment. Sobel and Bakris (eds.) Hanley and Belfus, Philadelphia, 2nd ed. 1999

Book Editor (Cont.)

BAKRIS GL. **The Kidney and Hypertension** Dunitz Publishing, London, 2003
Lip GYH and BAKRIS G **Handbook of Hypertension**, Science Press, NJ, 2005
Caralis D and BAKRIS GL. **Lower Extremity Arterial Disease**, Humana Press, 2005
Battguay, E, Lip G and BAKRIS, GL. **Comprehensive Hypertension**, Elsevier Press, 2006
BAKRIS, GL. **The Kidney in Cardiovascular Disease**, Dunitz Publishing, 2006
BAKRIS GL. **Therapeutic Strategies in Hypertension**. Clinical Pub. Oxford, UK, 2006
Bell DSH, O'Keefe JH, and BAKRIS GL (Eds.) **Handbook of Diabetic Hypertension** Physicians' Press, Royal Oak, MI, 2006
BAKRIS, GL. **Contemporary Diagnosis and Management of Hypertension and Diabetes**. Handbooks in Health Care Co. Newtown, PA, 2007
BAKRIS, GL **Microalbuminuria: Marker of Kidney and Cardiovascular Disease** Current Medicine Group, London, 2007
BAKRIS, GL **Cardiovascular Risk and the Kidney**, Dunitz Publishing, 2007-In preparation

ASSOCIATE Book Editor-

International Textbook of Cardiology Crawford MH, DiMarco JP and Paulus WJ (eds), 2004 and 2006 editions
Current Diagnosis & Treatment in Nephrology- The Lange Series, Nissensen A, Berns JS and Lerma E (Eds.) 2008 McGraw-Hill Pub., New York

Visiting Professorships

University of Hawaii, Nephrology Group-Honolulu, HI- July, 1992.
U. of So. Cal./LA County Hospital, Endocrine/Nephrology Sections-August, 1992
U of Miami School of Medicine, Nephrology section, Miami, FL., Jan.1994
Brookdale Medical Center, Nephrology section, Brooklyn, NY, October,1994
Royal University of Liverpool, Endocrinology Dept. -Liverpool, UK, Oct. 1994
U of Leicester, Hypertension/Medicine Dept- Leicester, UK, October, 1994
Guy's Hospital, Endocrinology Dept.- London, UK, June, 1995
Ohio State U Med. Center, Nephrology section-Columbus, Ohio, Mar, 1996
Allegheny University Med. Center, Nephrology-Philadelphia, PA, Nov, 1996
The Diabetes Institutes-Eastern Virginia Med School, Norfolk, VA, April, 1997
University of Washington, Nephrology Section, Seattle, WA, November, 1997
Ohio State University, Nephrology Section, Columbus, Ohio, February, 1998
U of Melbourne, Royal Melbourne Hosp, Melbourne, Australia, Mar. 1998
University of Maryland, Baltimore, MD, April, 1998
Joslin Diabetes Center, Boston, MA, October, 1999
Columbia University Medical Center, New York, NY April, 2000
University of Athens School of Medicine, Athens, Greece, September, 2000
Visiting Professorships (cont.)
King Faisal University Medical School, Riyadh, Saudi Arabia, January, 2001
Yale/New Haven Medical Center-New Haven, Conn., January, 2002

University of Florida, Gainesville, FL-April, 2003
Columbia Presbyterian/Cornell Hospitals, New York, May, 2003
Joslin Diabetes Center, January, 2004
Ottawa Heart Institute, Ottawa Canada, May, 2004
U of Washington, Seattle-Sept, 2004
U of Wisconsin, Madison-Nov., 2004
U of Alabama, Birmingham-Dec., 2004
U of Hawaii, Honolulu-Jan, 2005
U of California Los Angeles (UCLA)-Jan, 2005
Oxford University-Oxford, UK-Sept. 2005
East Virginia University, Norfolk, VA-Sept-2005
Kimmelstiel Lecturer (visiting professor)-U of Melbourne, Australia-July, 2006

INVITED LECTURES AND WORKSHOPS (summarized):

National and International Meetings & Symposia: Approximately 650 since 1985